Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 1 of 91 
CONFIDENTIAL    
Title Page  
Protocol Title:  Phase 4, Open -label Study to Evaluate 
Treatment Satisfaction With Erenumab in 
Patients With Migraine  
Short Protocol Title:  Erenumab Treatment Satisfaction Study  
Protocol Number:  20190389  
Investigational Product:  Erenumab -aooe  (AMG 334)  
Trade Name:  Aimovig® 
Sponsor  Name of Sponsor:  Amgen Inc.  
Address:  One Amgen Center Drive  
Thousand Oaks, CA 91320  
Telephone Number:  805-447-1000  
Protocol 
Approver  Name:  , MD  
Function:  Vice President , Global Development  
 
Key 
Sponsor 
Contact  Name:   
Address:  One Amgen Center Drive  
Thousand Oaks, CA 91320  
Telephone Number:   
Email Address:   
 
EudraCT Number:  Not applicable  
Study ID: [REMOVED]  
Protocol Version Date:  Document 
Version  Date  
Original  
Superseded 
Original  
Amendment 1  
Amendment 2  30 October 2020  
20 November 2020  
 
18 December 2020  
18 March 2022  
 
Data Elements Standards 
Version:  7.0 
 
This protocol was developed, reviewed, and approved in accordance with Amgen’s 
standard operating procedures.  This format and content of this protocol is aligned with 
Good Clinical Practice:  Consolidated Guidance (ICH E6).  
 

Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 2 of 91 
CONFIDENTIAL    
Confidentiality Notice  
 This document contains confidential information of Amgen Inc.  
This document must not be disclosed to anyone other than the site study staff and 
members of the institutional review board/ independent ethics committee/institutional 
scientific review board or equivalent.  
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent of 
Amgen Inc. 
If you have questions regarding how this document may be used or shared, call the 
Amgen Medical Information number:   US sites, 1 - 800-77-AMGEN; Amgen’s general 
number in the US, 1 -805-447-1000.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 3 of 91 
CONFIDENTIAL    
Investigator’s Agreement:  
I have read the attached protocol entitled Phase 4, Open -label Study to Evaluate 
Treatment Satisfaction With Erenumab in Patients With Migraine , dated 18 March 2022 , 
and agree to abide by all provisions set forth therein.   
I agree to comply with the I nternational Council for Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable 
national or regional regulations/guidelines.   
I agree to ensure that Financial Disclosure Statements will be complet ed by: me 
(including, if applicable, my spouse or legal partner and dependent children) and my 
subinvestigators (including, if applicable, their spouses or legal partners and dependent 
children) at the start of the study and for up to 1 year after the stud y is completed, if 
there are changes that affect my financial disclosure status.  
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigat ion 
without the prior written consent of Amgen Inc.  
 
_______________________________  
Signature  
 
_______________________________  ____________________________  
Name of Investigator     Date (DD Month YYYY)  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 4 of 91 
CONFIDENTIAL    
Table of Contents  
Table of Contents  ................................ ................................ ................................ ... 4 
1. Protocol Summary  ................................ ................................ ................................ .. 8 
1.1 Synopsis  ................................ ................................ ................................ ..... 8 
1.2 Study Schema  ................................ ................................ ...........................  14 
1.3 Schedule of Activities (SoA)  ................................ ................................ ...... 15 
2. Introduction  ................................ ................................ ................................ ...........  20 
2.1 Study Rationale  ................................ ................................ .........................  20 
2.2 Background  ................................ ................................ ...............................  21 
2.2.1  Disease  ................................ ................................ .....................  21 
2.2.2  Amgen Investigational Product Background:  
Erenumab  ................................ ................................ .................  21 
2.3 Benefit/Risk Assessment  ................................ ................................ ...........  22 
3. Objectives and Endpoints/Estimands  ................................ ................................ .... 23 
4. Study Design  ................................ ................................ ................................ ........  27 
4.1 Overall Design  ................................ ................................ ..........................  27 
4.2 Patient Input into the Study Design  ................................ ...........................  29 
4.3 Justification for Investigational Product Dose  ................................ ............  29 
4.4 End of Study  ................................ ................................ .............................  29 
5. Study Population  ................................ ................................ ................................ .. 29 
5.1 Inclusion Criteria  ................................ ................................ .......................  30 
5.2 Exclusion Criteria  ................................ ................................ ......................  31 
5.3 Subject Enrollment  ................................ ................................ ....................  33 
5.4 Screen Failures  ................................ ................................ .........................  34 
6. Study Intervention  ................................ ................................ ................................ . 34 
6.1 Study Interventions Administered  ................................ ..............................  35 
6.1.1  Investigational Products  ................................ ............................  35 
6.1.2  Non-investigational Products  ................................ .....................  35 
6.1.3  Medical Devices  ................................ ................................ ........  35 
6.1.4  Other Protocol -required Therapies  ................................ ............  36 
6.1.5  Other Intervention Procedures  ................................ ...................  36 
6.1.6  Product Complaints  ................................ ................................ ... 36 
6.1.7  Excluded Treatments, Medical Devices, and/or 
Procedures During Study Period  ................................ ...............  36 
6.2 Dose Modification  ................................ ................................ ......................  38 
6.2.1  Dose -[group/cohort] Study Escalation/De -escalation 
and Stopping Rules  ................................ ................................ ... 38 
6.2.2  Dosage Adjustments, Delays, Rules for Withholding or 
Restarting, Permanent Discontinuation of Amgen 
Investigational Product: Erenumab  ................................ ............  38 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 5 of 91 
CONFIDENTIAL    
6.2.3  Hepatotoxicity Stopping and Rechallenge Rules  .......................  39 
6.3 Preparation/Handling/Storage/Accountability  ................................ ............  39 
6.4 Measures to Minimize Bias:  Randomization and Blinding  .........................  39 
6.4.1  Method of Treatment Assignment  ................................ ..............  39 
6.4.2  Blinding  ................................ ................................ .....................  39 
6.5 Treatment Compliance  ................................ ................................ ..............  39 
6.6 Treatment of Overdose  ................................ ................................ .............  40 
6.7 Prior and Concomitant Treatment  ................................ .............................  40 
6.7.1  Migraine Preventive Medications  ................................ ...............  40 
6.7.2  Prior Treatment  ................................ ................................ .........  40 
6.7.3  Concomitant Treatment  ................................ .............................  40 
7. Discontinuation of Study Treatment and Subject 
Discontinuation/Withdrawal  ................................ ................................ ...................  40 
7.1 Discontinuation of Study Treatment ................................ ...........................  41 
7.2 Subject Discontinuation/Withdrawal From the Study  ................................ . 41 
7.2.1  Reasons for Removal From Washout Period, Run -in 
Period, or Invasive Procedures  ................................ .................  42 
7.2.2  Reasons for Removal From Study  ................................ .............  42 
7.3 Lost to Follow -up ................................ ................................ .......................  42 
8. Study Assessments and Procedures  ................................ ................................ .... 42 
8.1 General Study Periods  ................................ ................................ ..............  43 
8.1.1  Screening, Enrollment and/or Randomization  ............................  43 
8.1.2  Treatment Period  ................................ ................................ ....... 43 
8.1.3  End of Study  ................................ ................................ ..............  44 
8.2 General Assessments  ................................ ................................ ...............  44 
8.2.1  Informed Consent  ................................ ................................ ...... 44 
8.2.2  Demographics  ................................ ................................ ...........  44 
8.2.3  Medical History  ................................ ................................ ..........  44 
8.2.4  Physical Measurements  ................................ ............................  44 
8.3 Efficacy Assessments  ................................ ................................ ...............  45 
8.3.1  Treatment Satisfaction Questionnaire for Medication  .................  45 
8.3.2  Migraine Global Impression Item  ................................ ...............  45 
8.3.3  Migraine Functional Impact Questionnaire  ................................ . 45 
8.3.4  Expectation of Treatment Scale  ................................ .................  45 
8.3.5  Migraine Symptom Severity Scale  ................................ .............  45 
8.3.6  Migraine Interictal Burden Scale  ................................ ................  46 
8.3.7  Generalized Anxiety Disorder Scale  ................................ ..........  46 
8.3.8  Patient Health Questionnaire  ................................ .....................  46 
8.3.9  Electronic Diary  ................................ ................................ .........  47 
8.4 Safety Assessments  ................................ ................................ ..................  47 
8.4.1  Clinical Laboratory Assessments  ................................ ...............  47 
8.4.2  Adverse Events and Serious Adverse Events  ............................  47 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 6 of 91 
CONFIDENTIAL    
8.4.2.1  Time Period and Frequency for Collecting 
and Reporting Safety Event Information  ..................  48 
8.4.2.2  Method of Detecting Adverse Events and 
Serious Adverse Events  ................................ ..........  49 
8.4.2.3  Follow -up of Adverse Events and Serious 
Adverse Events  ................................ .......................  49 
8.4.2.4  Regulatory Reporting Requirements for 
Serious Adverse Events  ................................ ..........  50 
8.4.2.5  Safety Monitoring Plan  ................................ ............  50 
8.4.2.6  Pregnancy and Lactation  ................................ .........  50 
8.4.2.7  Adverse Device Effects  ................................ ...........  51 
8.5 Optional Substudy: Qualitative Interviews  ................................ .................  51 
8.5.1  Substudy Background and Rationale  ................................ .........  51 
8.5.2  Research Question and Objectives of the Qualitative 
Interview Substudy  ................................ ................................ .... 52 
8.5.3  Substudy Design  ................................ ................................ ....... 52 
8.5.4  Summary of Substudy Participation Criteria ...............................  53 
8.5.5  Substudy Duration and Substudy Procedures  ...........................  54 
8.5.6  Variables  ................................ ................................ ...................  55 
8.5.6.1  Substudy Outcome Variable(s)  ................................  55 
8.5.6.2  Exposure Variable(s)  ................................ ...............  56 
8.5.7  Substudy Data Analysis  ................................ .............................  56 
8.5.8  Collection of Safety Information and Product 
Complaints  ................................ ................................ ................  57 
8.5.8.1  Definition of Safety Events  ................................ ...... 57 
8.5.8.2  Safety Reporting Requirements  ..............................  57 
9. Statistical Considerations  ................................ ................................ ......................  58 
9.1 Statistical Hypotheses  ................................ ................................ ...............  58 
9.2 Sample Size Determination  ................................ ................................ ....... 58 
9.3 Populations for Analysis  ................................ ................................ ............  59 
9.3.1  Covariates  ................................ ................................ .................  59 
9.3.2  Subgroups  ................................ ................................ .................  59 
9.4 Statistical Analyses  ................................ ................................ ...................  60 
9.4.1  Planned Analyses  ................................ ................................ ...... 60 
9.4.1.1  Interim Analysis and Early Stopping 
Guidelines  ................................ ...............................  60 
9.4.1.2  Primary Analysis  ................................ .....................  60 
9.4.1.3  Final Analysis  ................................ ..........................  60 
9.4.2  Methods of Analyses  ................................ ................................ . 60 
9.4.2.1  General Considerations  ................................ ...........  60 
9.4.2.2  Efficacy Analyses  ................................ ....................  61 
9.4.2.3  Safety Analyses  ................................ ......................  62 
10. References  ................................ ................................ ................................ ...........  63 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 7 of 91 
CONFIDENTIAL    
11. Appendices  ................................ ................................ ................................ ...........  65 
11.1  Appendix 1.  List of Abbreviations  ................................ .............................  66 
11.2  Appendix 2.  Clinical Laboratory Tests  ................................ ......................  68 
11.3  Appendix 3.  Study Governance Considerations  ................................ ....... 69 
11.4  Appendix 4.  Safety Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  ................................ ....... 77 
Definition of Adverse Event  ................................ ................................ ....... 77 
11.5  Appendix 5.  Contraceptive Guidance and Collection of 
Pregnancy and Lactation Information  ................................ ........................  86 
 
List of Tables  
Table 1 -1.  Subject Study Visits Through Open -label Treatment Phase .........................  15 
Table 1 -2.  Schedule of Activities for Key Family Members  ................................ ...........  18 
Table 1 -3.  Optional Substudy: Schedule of Activities for Participating 
Subjects, Clinicians, and Key Family Members  ................................ ....... 19 
Table 6 -1.  Investigational Products  ................................ ................................ ...............  35 
Table 6 -2.  Excluded Treatments, Medical Devices, and Procedures  ............................  37 
Table 9 -1.  Half -width of 95% CI for Various Estimated Percentages With 
Effective Sample Size of 289 Subjects  ................................ ...................  58 
 
List of Figures  
Figure 1 -1.  Study Schema  ................................ ................................ ............................  14 
Figure 11 -1.  Sample Electronic Serious Adverse Event Contingency Report 
Form (paper -based form)  ................................ ................................ ........  83 
Figure 11 -2.  Pregnancy and Lactation Notification Forms  ................................ .............  90 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 8 of 91 
CONFIDENTIAL    
1. Protocol Summary  
1.1 Synopsis  
Protocol Title:  Phase 4, Open -label Study to Evaluate Treatment Satisfaction With 
Erenumab in Patients With Migraine  
Short Protocol Title:   Erenumab Treatment Satisfaction Study  
Study Phase:   4 
Indication:   Preventive treatment of migraine in adults  
Rationale  
Migraine is a prevalent and disabling neurological disorder, with a significant impact on 
the individual, family, workplace, and society.  Objectives commonly assessed in 
registrational clinical trials for migraine prevention include changes in monthly 
migraine days and use of acute migraine -specific medications.  These parameters, 
however, do not fully capture the whole breadth of the impact of migraine preventive 
treatments on the daily lives of patients and their families, including their satisfaction wi th 
treatment.  
There is interest in the migraine provider community not only for clinical outcomes data, 
but also associated patient -centric data (eg, treatment satisfaction and global impression 
of change in migraine from different perspectives such as th ose of patients, providers 
and key family members).  Health systems are also tracking patient satisfaction as a 
metric for quality of care delivery.  These factors begin to define a new treatment 
paradigm for migraine management that includes both clinical  and treatment -related 
satisfaction outcomes.  
The Erenumab Treatment Satisfaction Study is a phase 4 United States (US), 
open -label, interventional, prospective 24 -week study evaluating treatment satisfaction 
with erenumab as a preventive treatment in adul t subjects with episodic migraine (EM) 
or chronic migraine (CM) currently on 1 standard of care migraine prevention therapy.  
The study will measure change in subject satisfaction with erenumab and subject, 
clinician, and key family member global impressio n of change in subject’s migraine 
condition over the life of the study.  
This study seeks to mirror real -world US clinical practice by providing subjects and 
investigators the flexibility to optimize erenumab dosing while maintaining or 
discontinuing the e xisting migraine prevention therapy (ie, standard of care).  
 
Objective(s) and Endpoint(s)/Estimands  
 
Objectives  Endpoints  
Primary  
 To evaluate the effect of erenumab 
on medication -specific treatment 
satisfaction   Change from baseline in the 
Treatment Satisfaction Questionnaire 
for Medication (TSQM) overall 
satisfaction scale score at week 24, 
as measured by items 12 to 14 of the 
TSQM version 1.4  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 9 of 91 
CONFIDENTIAL    
Primary Estimand  
The estimand for the primary efficacy objective c onsists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoint, which is the change from baseline in TSQM overall satisfaction scale 
score at week 24, as measured by items 1 2 to 14 of the TSQM  
 There are 2 intercurrent events, discontinuation of investigational product (IP) due to 
lack of efficacy or adverse event, and discontinuation of IP due to other reasons.  The 
treatment effect of interest will be assessed for all subjects who receive  least 1 dose of 
IP and have a baseline score and at least 1 post -baseline score on the TSQM overall 
satisfaction scale.  A composite strategy will be used for subjects who discontinued IP 
due to lack of efficacy or adverse event with d ata after IP discontinuation, defined by 
the worst postbaseline value observed up to IP discontinuation (inclusive).  A 
hypothetical strategy will be used for those subjects who discontinued IP due to other 
reasons with data collected after IP discontinuat ion censored.  
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is the mean change from baseline in TSQM overall 
satisfaction scale score at week 24, as measured by items 12 to 14 of the TSQM  
The primary estimand for th e primary efficacy objective is the mean change from baseline in 
TSQM overall satisfaction scale score at week 24 in subjects with EM or CM who are currently 
on 1 standard of care migraine prevention therapy and who receive at least 1 dose of IP and 
have a  baseline and at least 1 post -baseline TSQM overall satisfaction scale score , and a 
composite strategy will be used for subjects who discontinued IP due to lack of efficacy or 
adverse event with data after IP discontinuation defined by the worst postbaseli ne value 
observed up to IP discontinuation (inclusive), while a hypothetical strategy will be used for 
those subjects who discontinued IP due to other reasons with data collected after IP 
discontinuation censored.  
Secondary  
 To assess the effect of erenumab on 
medication -specific treatment 
satisfaction   Achievement of overall satisfaction at 
week 24 as defined by subject 
reporting of satisfied, very satisfied, or 
extremely satisfied on Item 14 of the 
TSQM version 1.4  
The estimand for the secondary ef ficacy objective on treatment satisfaction consists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoint, which is achievement of overall satisfaction at week 24 as defined by 
subject reporting of satisfied, very satisfied, or extremely satisfied on Item 14 of the 
TSQM  
 There are 2 intercurrent events, discontinuation of IP due to lack of efficacy or adverse 
event, and discontinuation of IP due to other reasons.  The t reatment effect of interest 
will be assessed for all subjects who receive at least 1 dose of IP and have a baseline 
value and at least 1 post -baseline value for Item 14 of the TSQM.  A composite 
strategy will be used for subjects who discontinued IP due to  lack of efficacy or 
adverse event where they will be defined as not satisfied after IP discontinuation.  A 
hypothetical strategy will be used for those subjects who discontinued IP due to other 
reasons with data collected after IP discontinuation censored . 
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is the proportion of subjects who achieves overall 
satisfaction at week 24  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 10 of 91 
CONFIDENTIAL    
The estimand for the secondary efficacy objective on treatment -related satisfaction is the 
proportion of subjects who achieves overall satisfaction at week 24 as defined by subject 
reporting of satisfied, very satisfied, or extremely satisfied on Item 14 of the TSQM version 1.4, 
in subjects with EM or CM who are currently on 1 standard of care mi graine prevention therapy 
and who receive at least 1 dose of IP and have a baseline value and at least 1 post -baseline 
value for Item 14 of the TSQM.  A composite strategy will be used for subjects who 
discontinued IP due to lack of efficacy or adverse eve nt where they will be defined as not 
satisfied after IP discontinuation, while a hypothetical strategy will be used for those subjects 
who discontinued IP due to other reasons with data collected after IP discontinuation censored.  
 To assess the effect of erenumab on 
global impression of change in 
migraine (by subject, treating 
clinician, and key family member)   Improvement in subject global 
impression at week 24, as defined by 
subject reporting of much improved or 
a little improved on the migraine 
Global Im pression Item (mGI -I)  
 Improvement in treating clinician’s 
global impression at Week 24, as 
defined by treating clinician’s 
reporting of much improved or a little 
improved on the mGI -I for each 
individual subject  
 Improvement in key family member’s 
impress ion at week 24, as defined by 
key family member’s reporting of 
much improved or a little improved on 
the mGI -I for each individual subject  
The estimand for the secondary efficacy objectives on impression of change in migraine 
consists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoints, which include:  
 Improvement in subject global impression at week 24, as defined by subject 
reporting of much improved or a little improved on the mGI -I 
 Improvement in treating clinician’s global impression at week 24, as defined by the 
clinician’s reporting of much improved or a little improved on the mGI -I for each 
individual subject  
 Improvement in key family member’s glob al impression at week 24, as defined by 
family member’s reporting of much improved or a little improved on the mGI -I for 
each individual subject  
 There are 2 intercurrent events, discontinuation of IP due to lack of efficacy or adverse 
event, and discontinu ation of IP due to other reasons.  The treatment effect of interest 
will be assessed for all subjects who receive at least 1 dose of IP and have at least 
1 post-baseline value of each respective mGI -I item.  A composite strategy will be used 
for subjects w ho discontinued IP due to lack of efficacy or adverse event where they 
will be defined as not improved after IP discontinuation.  A hypothetical strategy will be 
used for those subjects who discontinued IP due to other reasons with data collected 
after IP discontinuation censored.  
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is the proportion of subjects who achieves impression of 
improvement at week 24.   
The estimand for the secondary efficacy objective on impression of change in migraine is the 
proportion of subjects who achieves global impression of migraine improvement at week 24 as 
defined by subject, treating clinician, or family member reporting of m uch improved or a little 
improved on the mGI -I, in subjects with EM or CM who are currently on 1 standard of care 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 11 of 91 
CONFIDENTIAL    
migraine prevention therapy and who receive at least 1 dose of IP and have at least 
1 post-baseline value of the respective mGI -I, and a compo site strategy will be used for 
subjects who discontinued IP due to lack of efficacy or adverse event where they will be 
defined as not improved after IP discontinuation, while a hypothetical strategy will be used for 
those subjects who discontinued IP due to other reasons with data collected after IP 
discontinuation censored.  
 To assess the effect of erenumab on 
subject functional impairment   Change from baseline in physical 
function domain score at week 24, as 
measured by the Migraine Functional 
Impact Ques tionnaire (MFIQ)  
 Change from baseline in usual 
activities domain score at week 24 as 
measured by MFIQ  
 Change from baseline in emotional 
function domain score at week 24 as 
measured by MFIQ  
 Change from baseline in social 
function domain score at week 24 as 
measured by MFIQ  
The estimand for the secondary efficacy objective on subject functional impairment consists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoints, which include:  
 Change from baseline in MFIQ physical function domain score at week 24  
 Change from baseline in MFIQ usual activities domain score at week 24  
 Change from baseline in MFIQ emotional function domain score at week 24  
 Change from baseline in MFIQ soci al function domain score at week 24  
 There are 2 intercurrent events, discontinuation of IP due to lack of efficacy or 
adverse event, and discontinuation of IP due to other reasons.  The treatment effect 
of interest will be assessed for all subjects who rec eive at least 1 dose of IP and have 
a baseline value and at least 1 post -baseline value of the respective MFIQ domain 
scores.  A composite strategy will be used for subjects who discontinued IP due to 
lack of efficacy or adverse event with data after IP di scontinuation defined by the 
worst postbaseline value observed up to IP discontinuation (inclusive).  A hypothetical 
strategy will be used for those subjects who discontinued IP due to other reasons with 
data collected after IP discontinuation censored.  
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is change from baseline in each MFIQ domain score at 
week 24  
The estimand for the secondary efficacy objective on subject functional impairment is the 
change from baselin e at week 24 in each MFIQ domain score, in subjects with EM or CM who 
are currently on 1 standard of care migraine prevention therapy and who receive at least 
1 dose of IP and have a baseline value and at least 1 post -baseline value in each MFIQ 
domain sco re, and a composite strategy will be used for subjects who discontinued IP due to 
lack of efficacy or adverse event with data after IP discontinuation defined by the worst 
postbaseline value observed up to IP discontinuation (inclusive), while a hypothetic al strategy 
will be used for those subjects who discontinued IP due to other reasons with data collected 
after IP discontinuation censored.  
 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 12 of 91 
CONFIDENTIAL    
Overall Design  
The study will comprise the following periods:  
 A combined screening/baseline period consisting of the following:  
 A screening visit (which may coincide with the first day of the baseline period) for 
the assessment of eligibility criteria  
 A baseline period of approximately 4 weeks (no less than 28 days ; up to 35 days) 
to collect data on migraine headaches and acute headache medication use using 
electronic diary (eDiary) and to assess compliance in eDiary usage  
 A 24-week open -label treatment period  
Subjects will sign the informed consent and be screened  at the screening visit; eligible 
subjects may enter the baseline period at the same visit or may delay baseline 
procedures up to 3 weeks after the screening visit.  At completion of the baseline period, 
those who meet eligibility criteria and choose to pr oceed will be enrolled and will enter 
the open -label treatment period.  
The treating clinician and a key family member (if available) for each participating 
subject will be invited to complete an mGI -I at weeks 12, 16, 20, and 24/End of Study 
(EOS).  The ke y family member must sign an informed consent before completing any 
study -specific procedures.  The same clinician and key family member of each subject 
should complete the mGI -I across all visits.  If the clinician or key family member is 
unable to comple te a visit, the assessment for that visit should be noted as missed.  
Qualitative interviews will be conducted with a selected subset of subjects, their treating 
clinicians, and key family members as part of an optional substudy.  These interviews 
will be u sed to provide qualitative information on satisfaction/improvement and details 
into the drivers of satisfaction and improvement that might not be captured by 
self-assessment alone.  
Number of Subjects  
Approximately 322 subjects will be enrolled into the  main study.  The ratio of EM:CM will 
be approximately 1:1 to allow for qualitative assessments of satisfaction and impression 
of change in migraine for the two migraine types.  A subset of approximately 20 enrolled 
subjects at select sites, their clinicia ns, and key family members will be invited to 
participate in an optional qualitative interview -based substudy with interviews to be 
conducted at the start and end of the study.  
Summary of Eligibility Criteria  
Subjects eligible for the study include tho se who are ≥  18 years of age, have a history of 
migraine with or without aura for ≥ 12 months before screening, have ≥  4 migraine days 
per month on average over the 3  months prior to screening, can be classified as EM or 
CM, report to their provider intole rance or insufficient response with their current 
preventive treatment, and demonstrate at least 75% compliance with the eDiary during 
the baseline period.  
Key family members eligible for the study should  be a family member/caregiver of an 
enrolled patient  and a person in the subject’s life with whom s/he interacts significantly 
on a day -to-day basis.  
Clinicians eligible for the study must be l icensed and practicing healthcare practitioners 
(HCPs) in the US and b e currently treating the subject on Study 201 90389.  
For a full list of eligibility criteria, please refer to Section 5.1 to Section 5.2. 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389   
Date:  18 March 2022  Page 13 of 91 
CONFIDENTIAL    
Treatments  
Subjects will receive e renumab 70 or 140 mg once every 4 weeks (Q4W) by 
subcutaneous (SC) injections during the 24 -week open -label treatment period.  
Erenumab will be packaged in a SureClick Autoinjector (AI)/Pen(s) containing 1 mL of 
70 mg/mL or 140 mg/mL of erenumab for SC injection.  
All subjects will be started on a 70 mg dose of erenumab at day 1 with provider 
discretion for dose optimization, which is recommended to be completed by week 12.  
Dose optimization will allow subjects to remain on 70 mg, increase the dose from 70 to 
140 mg, and if needed decrease the dose back down from 140 to 70 mg.  After week 12, 
it is highly recommended that all subjects remain on the week 12 erenumab dose for the 
rest of the study.  Additional dose adjustments after week 12 are not recommended and 
must only be made if deemed medically necessary by the investigator.  
All subjects will be required to enter the study on 1 standard of care preventive 
medication for their migraine.  Post -baseline, at their and the investigator’s discretion, 
subjects will be allowed to remain on their standard of care preventive treatment, or they 
may fully discontinue standard of care therapy.  Any changes to standard of care 
preventive treatment, including dose adjustments or tapering off medication, should be 
completed by the week 12 visit.  Standard of care dose adjustments are not permitted 
after week 12.  
Statistical Considerations  
Sample Size Considerations:   
The total sa mple size of approximately 322 subjects (effective sample size of 
289 assuming 10% dropout at Week 24) is driven by the precision of the proportion 
estimates for the binary secondary endpoints, which target a half -width of around 5% for 
estimated 95% confi dence intervals (CIs) (see Table 9 -1). 
Planned Analyses:   
The final analysis will be conducted when all enrolled subjects have completed the week 
24/EOS visit and the data have been entered, cleaned, and locked . 
The primary endpoint will be analyzed using a repeated measures mixed effects model, 
including baseline TSQM overall satisfaction scale score, visit, the prevailing erenumab 
dose from week 12 onward, and baseline monthly migraine days (MMD)  based on 
observed d ata.  The least -squares  mean (LSM) change from baseline in the TSQM 
overall satisfaction scale score at week 24 will be estimated, and the corresponding 
95% CI will be provided.  
Analysis of all secondary proportion endpoints will be descriptive only, where  point 
estimates of the proportion and the corresponding 95% CI will be provided for each 
endpoint.  All other secondary endpoints will be analyzed in a similar manner to the 
primary endpoint.  
For a full description of statistical analysis methods, please refer to Section  9. 
Statistical Hypotheses  
The study is descriptive in nature without a comparator arm, and as such no formal 
statistical hypothesis is defined.  
Sponsor Name:    Amgen Inc.  
 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:  18 March 2022  Page 14 of 91 
CONFIDENTIAL    
1.2 Study Schema  
Figure 1-1.  Study Schema  
  
* All subjects will be started on a 70 mg dose of erenumab at day 1 with provider discretion for dose optimization.  Dose optim ization will allow patients to remain 
on 70 mg, increase the dose from 70 mg to 140 mg, and if needed decrease the dose back down from 140 mg to 70 mg.  It is highly recommended that all 
erenumab dose adjustments be completed by week 12, after which all subjects should remain on the week 12 erenumab dose for th e rest of the study.  Additional 
dose adjustments after week 12 are not re commended and must only be made if deemed medically necessary by the investigator.  
** Baseline may begin on the same day as screening.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:  18 March 2022  Page 15 of 91 
CONFIDENTIAL    
1.3 Schedule of Activities (SoA)  
Table 1-1.  Subject Study Visits Through Open -label Treatment Phase  
PROCEDURE  Screening  
(up to 3  
weeks  
before 
baseline)c Baseline  
(4-5 
weeks 
before day 
1)c  Open -label Treatment Period (24 weeks)  
Notes  
Day 1e Week  
4 Week  
8 Week 
12 Week 
16 Week 
20 Week  
24/ 
EOS  
GENERAL  ASSESSMENTS  
Informed consent  X          
Inclusion and exclusion criteria  X          
Demographics  X          
Medical history  X          
Neurological medical history  X          
Gastrointestinal medical history  X          
Headache and migraine 
frequency medical history  X          
Migraine preventive medications 
review  X X X X X X X X X At screening, a review of the subject’s 
history of migraine preventive use (past 
and current) will be conducted. At 
subsequent visits, information will be 
collected regarding concomitant 
standard of care preventive status 
(ie, whether still taking and at what 
dose).  
Prior therapies review  X         Includes all prior medications (other 
than prior migraine preventive 
medications) that were being 
taken/used within 120 days prior to 
screening through the signing of the 
informed consent.  
Concomitant therapies review  X X X X X X X X X  
Eligibility criteria after baseline 
period    X       Compliance with eDiary usage will be 
assessed on day 1 to determine 
eligibility before any other day 1 
assessments.  
Physical measurements    X       Height/weight for BMI  
Page 1 of 3  
Footnotes are defined on the last page of this table.   
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:  18 March 2022  Page 16 of 91 
CONFIDENTIAL    
Table 1 -1.  Subject Study Visits Through Open -Label Treatment Phase  
PROCEDURE  Screening  
(up to 3  
weeks  
before 
baseline)c Baseline  
(4-5 
weeks 
before 
day 1)c Open -label Treatment Period (24 weeks)  
Notes  
Day 1e Week  
4 Week  
8 Week 
12 Week 
16 Week 
20 Week  
24/ 
EOS  
SAFETY ASSESSMENTS  
Adverse events    X X X X X X X  
Serious adverse events  X X X X X X X X X  
Adverse device effects    X X X X X X   
Product complaints    X X X X X X   
LABORATORY ASSESSMENTS  
Urine pregnancy test (females of 
childbearing potential only)  X  X   X   X Additional on -treatment pregnancy 
testing may be performed at the 
investigator’s discretion if there is 
suspicion that a female subject is 
pregnant or per local laws and 
regulations.  
CLINICAL OUTCOME ASS ESSMENTS  
eDiary   Daily     Daily   
ETS   X        
GAD -7   X   X   X  
MFIQ    X   X X X X  
mGI-I      X X X X To be completed by subject and 
clinician  
MIBS -4   X   X X X X  
MSSS    X   X X X X  
PHQ -9 Xd  X   X   X  
TSQM version 1.4    X   X X X X TSQM will assess satisfaction with 
standard of care migraine preventive 
medication at day 1 and only 
investigational product at subsequent 
time points.  
STUDY TREATMENT  
Amgen investigational product 
administratione    X X X X X X    
Page 2 of 3  
Footnotes are defined on the last page of this table.  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:  18 March 2022  Page 17 of 91 
CONFIDENTIAL    
Table 1 -1.  Subject Study Visits Through Open -Label Treatment Phase  
PROCEDURE  Screening  
(up to 3  
weeks  
before 
baseline)c Baseline  
(4-5 
weeks 
before 
day 1)c Open -label Treatment Period (24 weeks)  
Notes  Day 1e Week  
4 Week  
8 Week 
12 Week 
16 Week 
20 Week  
24/ 
EOS  
STUDY VISITS  
Onsite visita X X X   X   X  
Remote visit – site staff phone 
call with subjectb    X X  X X   
 Page 3 of 3  
BMI = body mass index; eDiary = electronic diary; EOS = End of Study; ETS = Expectation of Treatment Scale; GAD -7 = General Anxiety Disorder Scale; 
MFIQ  = Migraine Functional Impact Questionnaire; mGI -I = Migraine Global Impression Item; MIBS -4 = Migraine Interictal Burden Scale; MSSS  = Migraine Symptom 
Severity Scale; PHQ -9 = Patient Health Questionnaire; TSQM = Treatment Satisfaction Questionnaire for Medication  
a Screening, Baseline, day 1, week 12, and week 24/EOS visits are required to take place onsit e.  Subjects will be provided the doses necessary to continue 
erenumab monthly treatment at a non -investigative site (eg, subject’s home).  Additional onsite visits are optional at the investigator’s discretion.  
b For remote visits (ie, visits not conducte d onsite), visit data will be collected by site staff via telephone or via electronic device as applicable (eg, clinical outc omes 
assessments) . 
c Baseline may start on the same day as the screening visit.  
d Screening PHQ -9 is to assess eligibility and will  be collected on a paper form.  On -study PHQ -9 assessments will be collected on the subject’s eDiary device.  
e All day 1 procedures must be completed before investigational product is administered.  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:  18 March 2022  Page 18 of 91 
CONFIDENTIAL    
Table 1-2.  Schedule of Activities for Key Family Members  
PROCEDURE  Screening  
(up to 3 
weeks 
before 
baseline)a Baseline  
(4-5 weeks 
before 
day 1)a Open -Label Treatment Period (24 weeks)  
Notes  Day  
1 Week  
4 Week  
8 Week  
12 Week  
16 Week 
20 Week 
24/ 
EOS  
GENERAL ASSESSMENTS  
Informed consent for key family 
members  X    Signing of informed consent can occur 
any time at or before the week 12 visit. 
Informed consent must be signed 
before the week 12 mGI -I is 
administered.  
CLINICAL OUTCOMES ASSESSMENTS  
mGI-I      X X X X  
EOS = End of Study; mGI-I = Migraine Global Impression Item  
a Baseline may begin on the same day as the screening visit.  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:  18 March 2022  Page 19 of 91 
CONFIDENTIAL    
Table 1-3.  Optional Substudy: Schedule of Activities for Participating Subjects, Clinicians, and Key Family Members  
PROCEDURE  Screening  
(up to 3 
weeks  
before 
baseline)a Baseline  
(4-5 weeks 
before 
day 1)a Open -Label Treatment Period (24 weeks)  
Notes  Day  
1 Week  
4 Week  
8 Week  
12 Week  
16 Week 
20 Week 
24/ 
EOS  
HEALTH ECONOMIC ASSE SSMENTS  
Qualitative substudy informed 
consent  X        Written consent will be collected from 
subject and key family member.  
 
Signing of informed consent and 
participant screening can occur any  
time at or before the day 1 visit.  
Qualitative substudy interviews 
(conducted by third -party 
interviewer)b   X      X Participating subjects’ clinicians will 
also be interviewed.   
 
Interviewers will attempt to conduct the 
interview as soon as possible and 
within 7 days after day 1 and week 
24/EOS visits.  
EOS = End of Study  
a Baseline may begin on the same day as the screening visit.  
b Each participant (subject, clinician, and key family member) will be interviewed separately by the third -party interviewer.  
 
 
 
 
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 20 of 91 
CONFIDENTIAL    
2. Introduction  
2.1 Study Rationale  
Migraine is a prevalent and disabling neurological disorder, with a significant impact on 
the individual, family, workplace, and society.  Objectives commonly assessed in 
registrational clinical trials for migraine prevention include  changes in monthly 
migraine days (MMD) and use of acute migraine -specific medications.  These 
parameters, however, do not fully capture the whole breadth of the impact of migraine 
preventive treatments on the daily lives of patients and their families, in cluding their 
satisfaction with treatment.   
There is interest in the migraine provider community not only for clinical outcomes data, 
but also associated patient -centric data (eg, treatment satisfaction and global impression 
of change in migraine from dif ferent perspectives such as those of patients, providers, 
and key family members).  Health systems are also tracking patient satisfaction as a 
metric for quality of care delivery.  These factors begin to define a new treatment 
paradigm for migraine managem ent that includes both clinical and treatment -related 
satisfaction outcomes.  
The Erenumab Treatment Satisfaction Study is a phase 4 United States (US), 
open -label, interventional, prospective 24 -week study evaluating treatment satisfaction 
with erenumab as  a preventive treatment in adult subjects with episodic migraine (EM) 
or chronic migraine (CM) currently on 1 standard of care migraine prevention therapy.  
The study will measure change in subject satisfaction with erenumab and subject, 
clinician, and key  family member global impression of change in subject’s migraine 
condition over the life of the study.  
This study seeks to mirror real -world US clinical practice by providing subjects and 
investigators the flexibility to optimize erenumab dosing and maint ain or discontinue the 
existing migraine prevention therapy (ie, standard of care).  
The study will be the first to evaluate patient satisfaction in a real -world migraine setting 
using the Treatment Satisfaction Questionnaire for Medication (TSQM), a questi onnaire 
validated in the migraine population.  It will also be the first to validate the migraine 
Global Impression Item (mGI -I) in migraine patients, their treating clinician, and key 
family member.  With this validation work, it will be the first study t o allow the capture of 
information on impression of improvement in the patient’s overall condition from multiple 
perspectives: patient, clinician, and key family member.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 21 of 91 
CONFIDENTIAL    
2.2 Background  
2.2.1  Disease  
Migraine is a disabling disorder characterized by primary rec urrent headaches (referred 
to as attacks) with or without aura (ie, visual, sensory, and/or speech symptoms that 
occur just before or at the onset of migraine headache), lasting 4 to 72 hours (if not 
treated) with at least 2 of the following pain character istics: unilateral, pulsating, 
moderate or severe intensity, or aggravated by routine physical activity.  Migraine 
attacks are often accompanied by nausea, vomiting, and sensitivity to light 
(photophobia) and sound (phonophobia).  Migraine affects more tha n 10% of the world’s 
population (Robbins and Lipton, 2010), and the prevalence of migraine is approximately 
11.7% in the United States, 14.6% in Canada, and 14.7% in Europe (Stovner and 
Andree, 2010; Lipton et al, 2007).  
The patient burden and disability, as well as the societal impact, increase with higher 
attack frequency.  For this reason, migraine is categorized in 2 major classifications, 
according to frequency of migraine days per month: EM is typically defined as 0 to 
14 headache days per month ( Katsarava et al, 2012) .  According to the International 
Classification of Headache Disorders ( ICHD )-4 interim recommendations in 2020, 
EM is better defined as “Headache occurring on  15 days a month over the last 
3 months, which on some days is migraine” (Goa dsby & Evers, 2020).  Chronic 
migraine is defined as 15 or more headache days per months, at least 8  of which have 
to be typical migraine days , with m igraine prevention typically considered in individuals 
with ≥ 4 MMD  (Headache Classification Committee of the International Headache 
Society, 2018).  All patients suffering from migraine can be treated with acute 
medications, and those suffering from frequent/long -lasting attacks and/or significant 
disability induced by the attacks should be considered for pre ventive treatment (The 
American Headache Society Position Statement On Integrating New Migraine 
Treatments Into Clinical Practice , 2018; Antonaci et al, 2010; Evers et al, 2006).  
Reports suggest that out of the approximately 25% of patients with migraine in need of 
migraine prevention, only half of them receive migraine preventive treatments (Lipton et 
al, 2007).  
2.2.2  Amgen Investigational Product Background:  Erenumab  
Erenumab is a human immunoglobulin G2 monoclonal antibody that is directed against 
the canonical calcitonin gene -related peptide (CGRP) receptor complex and inhibits the 
action of CGRP.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 22 of 91 
CONFIDENTIAL    
Calcitonin gene -related peptide belongs to the calcitonin family of p eptides and is 
expressed in both the central and peripheral nervous systems.  It is prominently involved 
in the pathophysiology of migraine through nociceptive modulation in the 
trigeminovascular system (Goadsby et al, 2002; Tajti et al, 1999).  
As of the date of approval of this protocol, erenumab 70 mg and 140 mg subcutaneously 
(SC) every 4 weeks (Q4W) or once monthly (QM) has been approved in more than 
60 countries, including the US, Australia, Switzerland, and the European Union.  
A detailed description of the chemistry, pharmacology, efficacy, and safety  of erenumab 
is provided in the Investigator’s Brochure.  
2.3 Benefit/Risk Assessment  
Benefits  
Globally, the totality of data from phase 2 and phase 3 studies in subjects with CM and 
EM provides substanti al evidence for the efficacy and safety of erenumab in adults with 
migraine.  The key benefits of erenumab include reduction in MMD, reduction in acute 
migraine -specific medication use, as well as improvements in a range of other patient -
reported outcomes (PROs), favorable tolerability, low treatment discontinuation rates, 
convenience (Q4W injections with the option of self -administration), and rapid onset of 
effect.  
Risks  
The safety profile of erenumab has been favorable in clinical trials and in the 
post-marketing setting.  A limited number of adverse drug reactions (injection site 
reactions, constipation, muscle spasm, and pruritus) have been identified at low 
frequencies (  5) in clinical trials.  In the long -term use of erenumab, the safety profile  
remained consistent through 5 years of open -label treatment .  In post-marketing  
settings, hypertension, hypersensitivity reactions (including rash, angioedema and 
anaphylactoid reactions), and constipation with serious complications have been 
reported.  In addition, oral sores ( eg, stomatitis, mouth ulceration, oral mucosal 
blistering) , alopecia and rash ( eg, rash papular, exfoliative rash, rash erythematous, 
urticaria, blister)  have been observed in post -marketing surveillance .   
The above benefit risk a ssessment supports the conduct of this clinical trial.  Reference 
should be made to the currently approved  Investigator’s Brochure and Prescribing 
Information, where Aimovig is approved, for further data on erenumab.   
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 23 of 91 
CONFIDENTIAL    
3. Objectives and Endpoints/Estimands  
 
Objectives  Endpoints  
Primary  
 To evaluate the effect of erenumab 
on medication -specific treatment 
satisfaction   Change from baseline in the 
Treatment Satisfaction Questionnaire 
for Medication (TSQM) overall 
satisfaction scale score at week 24, 
as measured by items 12 to 14 of the 
TSQM version 1.4  
Primary Estimand  
The estimand for the primary efficacy objective c onsists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoint, which is the change from baseline in TSQM overall satisfaction scale 
score at week 24, as measured by items 1 2 to 14 of the TSQM  
 There are 2 intercurrent events, discontinuation of investigational product (IP) due to 
lack of efficacy or adverse event, and discontinuation of IP due to other reasons.  The 
treatment effect of interest will be assessed for all subjects who receive  least 1 dose of 
IP and have a baseline score and at least 1 post -baseline score on the TSQM overall 
satisfaction scale.  A composite strategy will be used for subjects who discontinued IP 
due to lack of efficacy or adverse event with d ata after IP discontinuation, defined by 
the worst postbaseline value observed up to IP discontinuation (inclusive).  A 
hypothetical strategy will be used for those subjects who discontinued IP due to other 
reasons with data collected after IP discontinuat ion censored.  
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is the mean change from baseline in TSQM overall 
satisfaction scale score at week 24, as measured by items 12 to 14 of the TSQM  
The primary estimand for the primary efficacy objective is the mean change from baseline in 
TSQM overall satisfaction scale score at week 24 in subjects with EM or CM who are currently 
on 1 standard of care migraine prevention therapy and who receive at le ast 1 dose of IP and 
have a baseline and at least 1 post -baseline TSQM overall satisfaction scale score , and a 
composite strategy will be used for subjects who discontinued IP due to lack of efficacy or 
adverse event with data after IP discontinuation defi ned by the worst postbaseline value 
observed up to IP discontinuation (inclusive), while a hypothetical strategy will be used for 
those subjects who discontinued IP due to other reasons with data collected after IP 
discontinuation censored.  
Secondary  
 To assess the effect of erenumab on 
medication -specific treatment 
satisfaction   Achievement of overall satisfaction at 
week 24 as defined by subject 
reporting of satisfied, very satisfied, or 
extremely satisfied on Item 14 of the 
TSQM version 1.4  
The estimand  for the secondary efficacy objective on treatment satisfaction consists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoint, which is achievement of overall satisfaction  at week 24 as defined by 
subject reporting of satisfied, very satisfied, or extremely satisfied on Item 14 of the 
TSQM  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 24 of 91 
CONFIDENTIAL    
 There are 2 intercurrent events, discontinuation of IP due to lack of efficacy or adverse 
event, and discontinuation of IP due to other reasons.  The treatment effect of interest 
will be assessed for all subjects who receive at least 1 dose of IP and have a baseline 
value and at least 1 post -baseline value for Item 14 of the TSQM.  A composite 
strategy will be used for subjects who discont inued IP due to lack of efficacy or 
adverse event where they will be defined as not satisfied after IP discontinuation.  A 
hypothetical strategy will be used for those subjects who discontinued IP due to other 
reasons with data collected after IP discontin uation censored.  
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is the proportion of subjects who achieves overall 
satisfaction at week 24  
The estimand for the secondary efficacy objective on treatment -related satisf action is the 
proportion of subjects who achieves overall satisfaction at week 24 as defined by subject 
reporting of satisfied, very satisfied, or extremely satisfied on Item 14 of the TSQM version 1.4, 
in subjects with EM or CM who are currently on 1 stan dard of care migraine prevention therapy 
and who receive at least 1 dose of IP and have a baseline value and at least 1 post -baseline 
value for Item 14 of the TSQM.  A composite strategy will be used for subjects who 
discontinued IP due to lack of efficacy  or adverse event where they will be defined as not 
satisfied after IP discontinuation, while a hypothetical strategy will be used for those subjects 
who discontinued IP due to other reasons with data collected after IP discontinuation censored.  
 To assess  the effect of erenumab on 
global impression of change in 
migraine (by subject, treating 
clinician, and key family member)   Improvement in subject global 
impression at week 24, as defined by 
subject reporting of much improved or 
a little improved on the mig raine 
Global Impression Item (mGI -I)  
 Improvement in treating clinician’s 
global impression at Week 24, as 
defined by treating clinician’s 
reporting of much improved or a little 
improved on the mGI -I for each 
individual subject  
 Improvement in key family m ember’s 
impression at week 24, as defined by 
key family member’s reporting of 
much improved or a little improved on 
the mGI -I for each individual subject  
The estimand for the secondary efficacy objectives on impression of change in migraine 
consists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoints, which include:  
 Improvement in subject global impression at week 24, as defined by subject 
reporting of much improved or a little improved on the mGI -I 
 Improvement in treating clinician’s global impression at week 24, as defined by the 
clinician’s reporting of much improved or a little improved on the mGI -I for each 
individual subject  
 Improvement in key family member’s glob al impression at week 24, as defined by 
family member’s reporting of much improved or a little improved on the mGI -I for 
each individual subject  
 There are 2 intercurrent events, discontinuation of IP due to lack of efficacy or adverse 
event, and discontinu ation of IP due to other reasons.  The treatment effect of interest 
will be assessed for all subjects who receive at least 1 dose of IP and have at least 
1 post-baseline value of each respective mGI -I item.  A composite strategy will be used 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 25 of 91 
CONFIDENTIAL    
for subjects w ho discontinued IP due to lack of efficacy or adverse event where they 
will be defined as not improved after IP discontinuation.  A hypothetical strategy will be 
used for those subjects who discontinued IP due to other reasons with data collected 
after IP discontinuation censored.  
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is the proportion of subjects who achieves impression of 
improvement at week 24.   
The estimand for the secondary efficacy objective on impression of change in migraine is the 
proportion of subjects who achieves global impression of migraine improvement at week 24 as 
defined by subject, treating clinician, or family member reporting of m uch improved or a little 
improved on the mGI -I, in subjects with EM or CM who are currently on 1 standard of care 
migraine prevention therapy and who receive at least 1 dose of IP and have at least 
1 post-baseline value of the respective mGI -I, and a compo site strategy will be used for 
subjects who discontinued IP due to lack of efficacy or adverse event where they will be 
defined as not improved after IP discontinuation, while a hypothetical strategy will be used for 
those subjects who discontinued IP due to other reasons with data collected after IP 
discontinuation censored.  
 To assess the effect of erenumab on 
subject functional impairment   Change from baseline in physical 
function domain score at week 24, as 
measured by the Migraine Functional 
Impact Ques tionnaire (MFIQ)  
 Change from baseline in usual 
activities domain score at week 24 as 
measured by MFIQ  
 Change from baseline in emotional 
function domain score at week 24 as 
measured by MFIQ  
 Change from baseline in social 
function domain score at week 24 as 
measured by MFIQ  
The estimand for the secondary efficacy objective on subject functional impairment consists of:  
 The target population, which includes subjects with EM or CM currently on 1 standard 
of care migraine prevention therapy  
 The endpoints, which include:  
 Change from baseline in MFIQ physical function domain score at week 24  
 Change from baseline in MFIQ usual activities domain score at week 24  
 Change from baseline in MFIQ emotional function domain score at week 24  
 Change from baseline in MFIQ soci al function domain score at week 24  
 There are 2 intercurrent events, discontinuation of IP due to lack of efficacy or 
adverse event, and discontinuation of IP due to other reasons.  The treatment effect 
of interest will be assessed for all subjects who rec eive at least 1 dose of IP and have 
a baseline value and at least 1 post -baseline value of the respective MFIQ domain 
scores.  A composite strategy will be used for subjects who discontinued IP due to 
lack of efficacy or adverse event with data after IP di scontinuation defined by the 
worst postbaseline value observed up to IP discontinuation (inclusive).  A hypothetical 
strategy will be used for those subjects who discontinued IP due to other reasons with 
data collected after IP discontinuation censored.  
 The treatment, which is erenumab 70 or 140 mg every 4 weeks  
 The summary measure, which is change from baseline in each MFIQ domain score at 
week 24  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 26 of 91 
CONFIDENTIAL    
The estimand for the secondary efficacy objective on subject functional impairment is the 
change from baselin e at week 24 in each MFIQ domain score, in subjects with EM or CM who 
are currently on 1 standard of care migraine prevention therapy and who receive at least 
1 dose of IP and have a baseline value and at least 1 post -baseline value in each MFIQ 
domain sco re, and a composite strategy will be used for subjects who discontinued IP due to 
lack of efficacy or adverse event with data after IP discontinuation defined by the worst 
postbaseline value observed up to IP discontinuation (inclusive), while a hypothetic al strategy 
will be used for those subjects who discontinued IP due to other reasons with data collected 
after IP discontinuation censored.  
 
non-GR AAS Styl e found: : N o Spaci ng  
 
Exploratory  
 To explore the effect of erenumab on 
the change from baseline in monthly 
medication -specific treatment 
satisfaction   Change from baseline in TSQM 
overall satisfaction scale score at 
weeks 12, 16, and 20 and mean over 
weeks 16, 20, and 24  
 Change from baseline in TSQM 
sub-scale domain scores at weeks 12, 
16, 20 and 24 a nd mean over weeks 
16, 20, and 24:  
‒ effectiveness  
‒ side effects  
‒ convenience  
 To explore the effect of erenumab on  
monthly global impression of 
improvement in migraine   Improvement in subject global 
impression at weeks 12, 16, and 20, 
as defined by subject reporting of 
much improved or a little improved on 
the mGI -I 
 Improvement in treating clinician’s 
global impression at weeks 12, 16, 
and 20, as defined by treating 
clinician’s reporting of much improved 
or a little improved on the mGI -I 
 Improvement in key f amily member’s 
global impression at weeks 12, 16, 
and 20, as defined by key family 
member’s reporting of much improved 
or a little improved on the mGI -I 
 To explore the effect of erenumab on 
the change from baseline in monthly 
functional impairment   Change from baseline in MFIQ 
functional impairment domain scores, 
at weeks 12, 16, and 20, and mean 
over weeks 16, 20, and 24:  
‒ Impact on physical function  
‒ Impact on usual activities  
‒ Impact on emotional function  
‒ Impact on social function  
 To explore the effect of erenumab on 
the change from baseline in the 
burden of migraine   Change from baseline in the Migraine 
Symptom Severity Scale (MSSS) total 
score at weeks 12, 16, 20, and 24 
and mean over weeks 16, 20, and 24  
 Change from baseline in the Migraine 
Interictal Bur den Scale (MIBS -4) total 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 27 of 91 
CONFIDENTIAL    
score at weeks 12, 16, 20, and 24 
and mean over weeks 16, 20, and 24  
 To explore the effect of erenumab on 
the change from baseline in number 
of monthly migraine days (MMD)   Change from baseline in mean MMD 
over weeks 16, 20, and 24   
 Change from baseline in MMD at 
weeks 16, 20, and 24  
 Achievement of at least a 50% 
reduction from baseline in mean 
MMD over weeks 16, 20, and 24  
 Achievement of at least a 50% 
reduction from baseline in MMD at 
weeks 16, 20, and 24  
 To explore the effect of  erenumab on 
the change from baseline in acute 
migraine -specific medication use   Change from baseline in mean 
monthly acute migraine -specific 
medication days over weeks 16, 20, 
and 24  
 Change from baseline in monthly 
acute migraine -specific medication 
days a t weeks 16, 20, and 24  
 To explore the effect of erenumab on 
the change from baseline in anxiety 
and depression   Change from baseline in General 
Anxiety Disorder scale (GAD -7) total 
score at weeks 12 and 24  
 Change from baseline in Patient 
Health Questionnaire (PHQ -9) total 
score at weeks 12 and 24  
 
4. Study Design  
4.1 Overall Design  
This is a phase 4 open -label study that will enroll subjects with EM or CM in an 
approximately 1:1 ratio.   The study will compri se the following periods:  
  A combined screening/baseline period consisting of the following:  
 A screening visit (which may coincide with the first day of the baseline period) for 
the assessment of eligibility criteria  
 A baseline period of approximately 4  weeks (no less than 28 days; up to 35 days) 
to collect data on migraine headaches and acute headache medication use using 
electronic diary (eDiary) and to assess compliance in eDiary usage  
 A 24-week open -label treatment period  
Subjects will sign the info rmed consent and be screened at the screening visit; eligible 
subjects may enter the baseline period at the same visit or may delay baseline 
procedures up to 3 weeks after the screening visit.  At completion of the baseline period, 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 28 of 91 
CONFIDENTIAL    
those who meet all eligi bility criteria and choose to proceed will be enrolled and will enter 
the open -label treatment period.  
For visits that take place onsite, study assessments will be performed by staff onsite with 
the exception of investigational product administration, whic h can be completed by site 
staff or by subject self -administration.  Subjects will be provided the doses necessary to 
continue erenumab monthly treatment at a non -investigative site (eg, subject’s home) 
between onsite visits, as detailed in the Schedule of  Activities ( Table 1 -1).  Site staff will 
contact subjects by telephone between scheduled onsite visits to perform a remote visit 
as described below and determine potential need for an onsite visit.  Changes in 
erenumab dosing may require an onsite visit.  Subjects may also contact the site at any 
time in between scheduled onsite visits and the investigator will determine if an 
additional unscheduled onsite visit is necessary.  
For visits not performed onsite, safety assessments, concomitant therapies review , and 
standard of care migraine preventive medication status will be performed by site staff on 
a telephone call with the subject and recorded in the subject’s medical record and 
electronic case report form (eCRF).  After speaking with site staff, subject or designee 
will administer investigational product to subject at a non -investigative site (eg, subject’s 
home).  The subject will record dose and lot number in their eDiary.  The dose data will 
be transcribed into the subject’s medical record and eCRF at the next onsite visit.   
All clinical outcomes assessments (COAs) detailed in the Schedule of Activities 
(Table  1-1) will be performed on the subject’s eDiary device regardless of visit location.  
The treating clinician and a key family member (if available ) for each participating 
subject will be invited to complete an mGI -I at weeks 12, 16, 20, and 24/EOS.  The key 
family member should be a person in the subject’s life with whom s/he interacts 
significantly on a day -to-day basis.  This person should have a deep understanding of 
the impact migraine has on the subject.  They should also be able to provide their 
perspective of change in the subject’s migraines over time.  The person the subject 
chooses to nominate can be anyone such as a spouse, daughter or son , parent, sibling, 
or other relative or the person with whom the subject is in a de facto relationship.  The 
key family member must sign an informed consent before completing any study -specific 
procedures.  The same clinician and key family member of each subject should 
complete the mGI -I across all visits.  If the clinician or key family member is unable to 
complete a visit, the assessment for that visit should be noted as missed.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 29 of 91 
CONFIDENTIAL    
4.2 Patient Input into the Study Design  
The overall study design is describe d by a study schema in Section 1.2.  The endpoints 
are defined in Section 3. 
Approximately 322 subjects will be enrol led in the study.  The ratio of EM:CM will be 
approximately 1:1 to allow for qualitative assessments of satisfaction and impression of 
change in migraine for the 2 migraine types.  A subset of approximately 20 enrolled 
subjects at selected sites, their cli nicians and key family members will be invited to 
participate in an optional qualitative interview -based substudy with interviews to be 
conducted at the start and end of the study.  
Subjects in this clinical investigation shall be referred to as “subjects.”   Clinicians and 
key family members will be referred to as “participants.”  For the sample size 
justification, see Section 9.2. 
4.3 Justification for Investigational Product Dose  
Erenumab 70 and 140 mg SC Q4W are approved in Europe and the US for the 
prevention of migraine in adults.  Regulatory approval was granted on the basis of 
established superiority against placebo for each dose in 4 independent r andomized 
clinical studies (1 CM and 3 EM) ( Sun et al, 2016; Goadsby et al, 2017; Tepper et al, 
2017; Dodick et al, 2018 ). 
4.4 End of Study  
An individual subject is considered to have completed the study if he/she has completed 
the last visit  shown in the Schedule of Activities .  The total study duration for an 
individual subject, including the screening/baseline period and 24 -week open -label 
treatment period, is approximately 28 to 32 weeks.  
The end of study date is defined as the date when the last subjec t across all sites is 
assessed or receives an intervention for evaluation in the study (ie, last subject last 
visit), following any additional parts in the study (eg, long -term follow up), as applicable.  
5. Study Population  
Investigators will be expected to maintain a screening log of all potential study 
candidates that includes limited information about the potential candidate (eg, date of 
screening ).  This log may be completed and updated via an Interactive Response 
Technology (IRT) system.  
Eligibility c riteria will be evaluated during screening and baseline period.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 30 of 91 
CONFIDENTIAL    
Before any study -specific activities/procedures, the appropriate written informed consent 
must be obtained (see Section 11.3). 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, will not be provided.  
5.1 Inclusion Criteria  
Subjects are eligible to be included in the study only if all of the following criteria apply:  
101 Age ≥ 18 years upon entry into screening  
102 Subject has provided informed consent prior to initiation of any study specific 
activities/procedures.  
103 History of migraine (with or w ithout aura) for ≥ 12 months before screening 
according to the International Headache Society (IHS ) Classification  ICHD -III 
(Headache Classification Committee of the International Headache Society, 
2018) based on medical records and/or patient self -report  
104 Migraine frequency: ≥  4 migraine days per month on average across the 
3 months prior to screening  
105 History of CM or EM migraine across the 3 months prior to screening:  
 CM is defined as: ≥  15 headache days a month of which ≥  8 headache days 
meet criteria as migraine days per subject self -report and investigator 
assessment  
 EM is defined as: <  15 headache days a month over the last 3  months, 
which  on some days  is migraine, but does not fulfil ICHD -3 criteria  for CM 
per subject self -report and investigator asses sment  
106 Subject reports to their provider intolerance or insufficient response with their 
current preventive treatment.  Insufficient response is defined as insufficient 
reduction in headache frequency, duration, or severity at the generally accepted 
therape utic dose for at least 6 weeks and is based on the investigator's 
assessment.  
107 Concomitant treatment with 1 migraine preventive medication is required under 
the following conditions:  
 Drug regimen (ie, formulation, frequency of use and dose) is stable for 
≥ 2 months prior to baseline period start  or injection paradigm is stable for 
2 injection cycles (acceptable range of injection frequency is every 10 to 
16 weeks) AND  
 Drug regimen or injection paradigm is at generally accepted doses and 
frequency for its use  in migraine AND  
 Drug regimen or injection paradigm is not anticipated to change during the 
baseline period AND  
 Drug regimen or injection paradigm is either:  
 not anticipated to change post -baseline OR  
 anticipated to be fully discontinued irrespective of tapering off schedules 
by no later than end of week 12  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 31 of 91 
CONFIDENTIAL    
 Medication is 1 of the following:  
 Divalproex sodium, sodium valproate, topiramate  
 Beta blockers (eg, atenolol, bisoprolol, metoprolol, nadolol, nebivolol, 
pindolol, propranolol, timolol)  
 Tricyclic ant idepressants (eg, amitriptyline, nortriptyline, protriptyline)  
 Duloxetine, milnacipran  
 Verapamil   
 Lisinopril, candesartan  
 Clonidine, guanfacine  
 Cyproheptadine  
 OnabotulinumtoxinA (subjects using concomitant 
onabotulinumtoxinA  for migraine  prevention are  allowed [but not 
required] to also take one oral preventive migraine medication)  
During the baseline period:  
108 Must have ≥ 4 MMD based on the eDiary data during the last 28 days of the 
baseline (if longer than 28 days)  
110 Must have d emonstrated ≥ 75% compliance with the eDiary, based on the last 
28 days of the baseline period (if longer than 28 days)  
5.2 Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply:  
Disease Related  
201  50 years of age at migraine onset  
202 History of cluster headache or hemiplegic migraine headache  
203 Unable to differentiate migraine from other headaches  
Other Medical Conditions  
204 Malignancy (except non -melanoma skin cancers, cervical or breast ductal 
carcinoma  in situ) within the last 5 years  
205 Evidence of substance -related disorders (eg, abuse, misuse, or addiction), 
addictive disorders (eg, pathological gambling), or "recreational use" of illicit 
drugs within 12  months prior to initial screening, based on medic al records, 
patient self -report, or positive urine drug test performed locally at investigator’s 
discretion during screening (with the exception of prescribed medications such as 
opioids or barbiturates that may result in a positive urine drug test)  
206 Active  chronic pain syndromes (eg, fibromyalgia and chronic pelvic pain)  
207 History of major psychiatric disorder ( eg, schizophrenia or other psychotic 
disorders, bipolar disorder, obsessive -compulsive disorder, post -traumatic stress 
disorder), or current evidence of moderately severe or severe depression based 
on a Patient Health Questionnaire -9 (PHQ -9) total score  ≥ 15 at screening  
 Subjects with history of anxiety disorder and/or major depressive disorder are 
permitted in the study if they are considered by the in vestigator to be stable 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 32 of 91 
CONFIDENTIAL    
(with PHQ -9 < 15) and are taking no more than 1 medication for each 
disorder.   
 For subjects taking antianxiety and/or antidepressant medication,  dose must 
be stable for at least 3 months prior  to the start of the baseline phase.  
208 The subject is at risk of self -harm or harm to others as evidenced by past suicidal 
behavior.  
Prior/Concomitant Therapy  
209 No therapeutic response with >  3 of the following 9 medication categories for 
preventive treatment of migraine after an adequate therapeut ic trial.  These 
medication categories are:  
 Category 1:  Topiramate  
 Category 2:  Other antiepileptics (eg, divalproex sodium, sodium valproate, 
gabapentin)  
 Category 3:  Beta blockers  
 Category 4:  Tricyclic antidepressants  
 Category 5:  Other antidepressants  (eg, serotonin -norepinephrine reuptake 
inhibitors, selective serotonin -reuptake inhibitors)  
 Category 6:  Calcium channel blockers (eg, verapamil, amlodipine, cinnarizine, 
lomerizine) or calcium antagonists (eg, flunarizine)  
 Category 7:  Angiotensin recept or blockers (eg, candesartan) or 
angiotensin -converting enzyme (ACE) inhibitors (eg, lisinopril)  
 Category 8:  Other drugs used for migraine prevention  
No therapeutic response is defined as no reduction in headache frequency, 
duration, or severity after adm inistration of the medication for at least 6  weeks at 
the generally -accepted therapeutic dose(s) based on the investigator’s 
assessment.     
The following scenarios do not constitute lack of therapeutic response:  
 Lack of sustained response to a medication  
 Failure to tolerate a therapeutic dose  
210 Used a prohibited medication, device, or procedure listed in Section 6.1.7  and 
Table 6 -2.  
211 Anticipated to require any excluded medication, device, or procedure  during the 
study.  
220 Any prior exposure to erenumab.  
221 Use of gepants for migraine prevention.  
222 Previously treated with a ligand -based anti -CGRP monoclonal antibody 
(ie, fremanezumab , galcanezumab, and/or eptinezumab) in a manner 
consistent with migraine pre vention that either:  
(a) in the opinion of the investigator, did not offer any evidence of a 
therapeutic response, OR  
(b) was discontinued for  12 weeks from the date of initial screening, OR  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 33 of 91 
CONFIDENTIAL    
(c) was previously discontinued due to a known adverse drug reaction.  
Prior/Concurrent Clinical Study Experience  
212 Currently receiving treatment in another investigational device or drug study, or 
less than 90 days or 5 half -lives (for investigational drugs), whichever is longer,  
since ending treatment on another investigation al device or drug study(ies ).  
Other Exclusions  
213 Female subjects of childbearing potential unwilling to use 1 acceptable method of 
contraception (see Section 11.5) during treatment and for an additional 16 weeks 
after the last dose of investigational product  
214 Female subjects who are breastfeeding or who plan to breastfeed while on study 
through 16 weeks after the last dose of investigational product  
215 Female subjects planning to become pregnant while on study through 16 w eeks 
after the last dose of investigational product  
216 Female subjects of childbearing potential with a positive pregnancy test 
assessed at screening and/or day 1 by a urine pregnancy test  
217 Subject has known sensitivity to any of the products [or components] t o be 
administered during dosing.  
218 Subject likely to not be available to complete all protocol -required study visits or 
procedures, and/or to comply with all required study procedures (eg, COAs) to 
the best of the subject and investigator’s knowledge.  
219 Histor y or evidence of any other clinically significant disorder, condition or 
disease (with the exception of those outlined above) that, in the opinion of the 
investigator or Amgen physician, if consulted, would pose a risk to subject safety 
or interfere with t he study evaluation, procedures or completion.  
5.3 Subject Enrollment  
Before subjects or key family members begin participation in any study -specific 
activities/procedures, Amgen requires a copy of the site’s written institutional review 
board/independent ethics committee (IRB/IEC)  approval of the protocol, informed 
consent form, and all other subject information and/or recruitment material, if applicable 
(see Section 11.3). 
The subject and key family member must personally sign and date the IRB/IEC and 
Amgen approved informed consent before commencement of study -specific procedures.  
A subject is considered enrolled when the investigator decides that t he subject has met 
all eligibility criteria.  This should occur on study day 1, after completion of the screening/ 
baseline period .  The investigator is to document this decision and date in the subject’s 
medical record and in/on the Subject Enrollment eCR F. 
Each subject who enters into the screening period for the study (defined as when the 
subject signs the informed consent form ) receives a unique subject identification number 
before any study -related activities/procedures are performed.  The subject iden tification 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 34 of 91 
CONFIDENTIAL    
number will be assigned by the IRT system .  This number will be used to identify the 
subject throughout the clinical study and must be used on all study documentation 
related to that subject.  
The subject identification number must remain constan t throughout the entire clinical 
study; it must not be changed after initial assignment, including if a subject is 
rescreened.  
Sites that do not enroll subjects within 3 months of site initiation may be closed.  
5.4 Screen Failures  
Screen failures are defin ed as subjects who consent to participate in the clinical study 
but are not subsequently enrolled in the study.  A minimal set of screen failure 
information will be collected that includes demography, screen failure details, eligibility 
criteria, and any s erious adverse events.  
Individuals who do not meet the criteria for participation in this study (screen failure) may 
be rescreened once if, in the opinion of the investigator, the reason for the initial screen 
failure has been resolved or is no longer appl icable .  Refer to Section 8.1.1 . 
6. Study Intervention  
Study intervention is defined as any investigational product(s), non -investigational 
product(s), placebo, combination product(s), or medical device(s) intended to be 
administered to a study subject according to the study protocol.  
Note that in several countries, investigational product and non -investigational product 
are referred to as investigational medicinal product and non -investigational medicinal 
product, respecti vely. 
A summary of the dosing and administration of each treatment  is shown in  Table 6 -1 
below.  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 35 of 91 
CONFIDENTIAL    
6.1 Study Interventions Administered  
6.1.1  Investigational Products  
Table 6-1.  Investigational Products  
Study Treatment 
Name  Amgen Investigational Product:a 
Erenumab  
Dosage 
Formulation  Erenumab will be packaged in a SureClick AI/Pen containing 1 mL of 
70 or 140 mg/mL of erenumab formulated with sodium acetate, sucrose, 
and polysorbate 80.  
Unit Dose 
Strength(s)/  
Dosage Level(s) 
and Dosage 
Frequency  Erenumab 70 or 140 mg will be administered subcutaneously every 
4 weeks.  
Route of 
Administration  Subcutaneous injection  
Accountability  The quantity, start date, and lot number(s) of investigational product are 
to be recorded on each subject’s eCRF.  
Dosing 
Instructions  On day 1, erenumab may be administered by site staff or 
self-administered by the subject, under site staff’s supervision, at the 
investigator’s discretion.  At remaining onsite visits, erenumab will be 
administered to subjects by site staff or by subject self -administration.  
Between onsite visits, subjects will continue dosing by self -administration 
or administration by a designated person every 4 weeks in a 
non-investigator site setting (eg, at subject ’s home).  
Device  AI/Pen  
AI = autoinjector; eCRF = electronic case report form  
a Erenumab will be manufactured and packaged by Amgen and distributed using Amgen clinical study drug 
distribution procedures.  
 
6.1.2  Non-investigational Products  
Non-investigational products will not be used in this study.  
6.1.3  Medical Devices  
The investigational medical device provided by Amgen for use in this study is the 
erenumab SureClick Autoinjector Pen (AI/Pen) (Table 6 -1). 
The erenumab SureClick AI/Pen is a single use disposable, handheld mechanical 
“spring -based” device for fixed dose SC injection of erenumab 1 mL deliverable volume.  
Other non -investiga tional medical devices may be used in the conduct of this study as 
part of standard care.  
Non-Amgen non -investigational medical devices (eg, syringes, sterile needles), that are 
commercially available are not usually provided or reimbursed by Amgen (except , for 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 36 of 91 
CONFIDENTIAL    
example, if required by local regulation).  The investigator will be responsible for 
obtaining supplies of these devices.  
6.1.4  Other Protocol -required Therapies  
Other protocol -required therapies will not be used in this study.  
6.1.5  Other Intervention Pro cedures  
Other intervention procedures will not be used in this study.  
6.1.6  Product Complaints  
A product complaint is any written, electronic or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety,  effectiveness, or 
performance of a drug , combination product or device after it is released for 
distribution to market or clinic by either (1) Amgen or (2) distributors or partners for 
whom Amgen manufactures the material.  This includes all components di stributed 
with the drug, such as packaging drug containers, delivery systems, labeling, and 
inserts.  
This includes  any investigational /noninvestigational  product(s), device(s) or 
combination product(s) provisioned and/or repackaged/modified by Amgen  SureC lick 
AI pen . 
Any product complaint(s) associated with an investigational product(s) , 
noninvestigational product(s), devices(s), or combination product(s) supplied by 
Amgen are to be reported.  
6.1.7  Excluded Treatments, Medical Devices, and/or Procedures During 
Study Period  
Subjects are required to be on 1 migraine preventive medication to be eligible for the 
study.  In addition to the 1 migraine preventive medication required for eligibility, subjects 
may be taking up to 1 additional medication from the  list provided below, provided that 
this medication (1) is being taken for an indication other than migraine prevention, 
(2) has been stable for at least 3 months prior to the start of the baseline period, and 
(3) is expected to remain stable during the st udy.  If a subject is receiving 
onabotulinumtoxinA for migraine prevention, one oral migraine preventive 
medication in addition to onabotulinumtoxinA is permitted.   
Initiation of any new oral migraine preventive medication is prohibited from 2  months 
before the start of the baseline period and throughout the study.  Such medications 
include:  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 37 of 91 
CONFIDENTIAL    
 Antiepileptics (eg, divalproex sodium, sodium valproate, topiramate, 
carbamazepine, levetiracetam)  
 Angiotensin receptor blockers (eg, candesartan) or ACE inhibitors (eg, lisinopril)  
 Beta blockers  
 Calcium channel blockers (eg, verapamil, amlodipine, cinnarizine) or calcium 
antagonists (eg, flunarizine)  
 Tricyclic antidepressants  
 Other antidepressants (eg, serotonin -norepinephrine reuptake inhibitors, 
selective serot onin-reuptake inhibitors)  
 Other drugs or supplements used for migraine prevention (eg, clonidine, 
guanfacine, methysergide, cyproheptadine, pizotifen)  
Initiation of botulinum toxin for any indication involving the head, face, or neck 
region is prohibited if less than 2  injection cycles of dose stability and injection 
paradigm.  Only onabotulinumtoxinA formulation will be allowed in the head, face, 
or neck region.  All other botulinum toxin formulations are only allowed in 
anatomic regions outside of the head, face, and neck.   
Additional excluded treatments, medical devices, and procedures are provided in 
Table  6-2. 
Table 6-2.  Excluded Treatments, Medical Devices, and Procedures  
Prohibited Medications, Devices, and Procedures  Time Period for Exclusion  
Ergotamine -derivatives, steroids, and triptans used for 
migraine prevention  2 months before the start of the 
baseline period and throughout the 
study  
Use of the following medications for the acute treatment 
of migraine for ≥ 4 days/month:  
 Barbiturates and/or butalbital -containing 
analgesics  
 Opioid and/or opioid -containing analgesics  2 months before the start of the 
baseline period and throughout the 
study  
Gepants for migraine prevention (eg, atogepant)  
Use of the following medications for acute treatment 
of migraine for  6 days/month : 
 Gepants (eg, rimegepant and ubrogepant)  
 Lasmiditan  Throughout screening and 
baseline , and while on  study  
Page 1 of 2  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 38 of 91 
CONFIDENTIAL    
Prohibited Medications, Devices, and Procedures  Time Period for Exclusion  
Anti-CGRP monoclonal antibodies (ie, eptinezumab, 
galcanezumab, gremanezumab)  12 weeks before the start of the 
screening period, and 
throughout the study  
Previously treated and currently being treated with 
erenumab  At any time in the past , 
throughout screening/baseline, 
and while on study  
Investigational medications  90 days or 5 half -lives (whichever is 
longer) before the start of the 
screening period and throughout 
the study  
For any indication: Devices (eg, neuromodulation 
devices) or procedures (eg, nerve blocks, trigger -point 
injections, and acupuncture) depending on anatomic 
region  and impact.  2 months before the start of the 
baseline period and throughout the 
study  
Cognitive behavioral therapy (CBT), biofeedback, and 
psychotherapy for migraine prevention .  
Note: Subjects on a stable, maintenance phase of these 
therapies for migraine will be allowed to participate. 
Note: Stable, maintenance phase of CBT is defined as 
≥ 6 weekly or biweekly sessions administered by 
adequately trained psychologists and only “booster” 
sessions at a monthly, bimonthly, or quarterly frequency 
at least 3 months before the star t of the screening 
period.  3 months before the start of the 
baseline period and throughout the 
study  
Note: Subjects who have 
discontinued CBT within 3  months 
prior to the start of the baseline 
phase are eligible for the study 
provided that there is evidenc e of 
CBT failure/lack of efficacy prior to 
initial screening (per medical 
records or investigator’s 
assessment).  
Page 2 of 2  
ACE = angiotensin -converting enzyme; CBT = cognitive behavioral therapy ; CGRP = calcitonin gene  
related peptide .  
 
6.2 Dose Modification  
6.2.1  Dose -[group/cohort] Study Escalation/De -escalation and Stopping 
Rules  
Dose -cohort study escalation/de -escalation and stopping rules do not apply to this study.  
6.2.2  Dosage Adjustments, Delays, Rules for Withholding or Restarting, 
Permanent Di scontinuation of Amgen Investigational Product: 
Erenumab  
All subjects will be started on a 70 mg dose of erenumab at day 1 with provider 
discretion for dose optimization, which is recommended to be completed by week 12.  
Dose optimization will allow pati ents to remain on 70 mg, increase the dose from 70 to 
140 mg, and if needed decrease the dose back down from 140 to 70 mg.  It is highly 
recommended that all erenumab dose adjustments be completed by week 12, after 
which all subjects should remain on the w eek 12 erenumab dose for the rest of the 
study.  Additional dose adjustments after week 12 are not recommended and must only 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 39 of 91 
CONFIDENTIAL    
be made if deemed medically necessary by the investigator.  All erenumab dose 
changes, regardless of timing, will require an onsite  visit. 
The reason for each dose change of erenumab is to be recorded on each subject’s 
eCRF (s). 
At any time during the study, the investigator may discontinue investigational product 
administration for any subject who experiences a severe or life -threaten ing adverse 
event reported by the investigator to be related to investigational product.  Refer to 
Section 8.4.2  for details regarding adverse event reporting.  
6.2.3  Hepatotoxicity Stopping and Rechallenge Rules  
No samp les assessing hepatotoxicity will be collected in this study.  
6.3 Preparation/Handling/Storage/Accountability  
Guidance and information on drug accountability for the investigational product and 
device  will be provided to the site.  
6.4 Measures to Minimize Bias:  Randomization and Blinding  
6.4.1  Method of Treatment Assignment  
Subjects who meet eligibility criteria and enroll in the study will be assigned to treatment 
with erenumab 70 mg initially, as defined in Section 6.2.2. 
The enrollment  date is to be documented in the subject’s medical record and on the 
Subject Enrollment eCRF.  
6.4.2  Blinding  
This is an open -label study; blinding procedures are not applica ble. 
6.5 Treatment Compliance  
Site staff will train subjects on self -administration of erenumab at the day 1 visit.  At 
subsequent onsite visits, subjects will receive erenumab administration directly from the 
investigator or designee or will self-administer the dose in the clinic under medical 
supervision.  The date and lot number of each dose administered in the clinic will be 
recorded in the source documents and recorded in the eCRF.  
When subjects self -administer erenumab at home, they shoul d enter the dose and lot 
number in the eDiary for each dose.  The data will be transcribed into the subject’s 
medical record and eCRF at the next onsite visit.  
Noncompliance is to be documented in the medical file and will be reflected in the eCRF.  
Noncom pliant subjects are to be re -educated on the importance of adhering to the 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 40 of 91 
CONFIDENTIAL    
investigational product administration schedule and reminded that repeated cycles of 
noncompliance could be a reason for discontinuation of study treatment.  
6.6 Treatment of Overdose  
Overdose with this product has not been reported.  No specific antidote exists.  In the 
case of an overdose, the subject should be treated symptomatically, and supportive 
measures implemented as necessary.  
6.7 Prior and Concomitant Treatment  
6.7.1  Migraine Pre ventive Medications  
All prior and current migraine preventive therapies will be collected.   
All subjects will be required to enter the study on 1 standard of care preventive 
medication for their migraine.  Subjects will be allowed to remain on their standa rd of 
care therapy during the study or fully discontinue the standard of care therapy by the 
week 12 visit.  Standard of care therapy status (ie, continued or discontinued) is to be 
recorded.  
6.7.2  Prior Treatment  
All prior therapies other than prior migraine pr eventive medications that were being 
taken/used from 120 days before screening through the signing of the informed consent 
will be collected in the concomitant medication eCRF.  
6.7.3  Concomitant Treatment  
Throughout the study, investigators may prescribe any con comitant medications or 
treatments deemed necessary to provide adequate supportive care except for those 
listed in Section 6.1.7 . 
Concomitant therapies are to be collected from the signing of  informed consent  through 
the end of study in the concomitant medication eCRF . 
7. Discontinuation of Study Treatment and Subject 
Discontinuation/Withdrawal  
Subjects have the right to withdraw from investiga tional product, protocol procedures, or 
the study as a whole at any time and for any reason without prejudice to their future 
medical care by the physician or at the institution.  
The investigator and/or sponsor can decide to withdraw a subject(s) from inve stigational 
product, device, protocol procedures, or the study as a whole at any time prior to study 
completion for the reasons listed in  Section 7. 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 41 of 91 
CONFIDENTIAL    
7.1 Discontinuation of Study Treatment  
Subjects can decline to continue receiving investigational product and/or procedures at 
any time during the study but continue participation in the study.  If this occurs, the 
investigator is to discuss with the subje ct the appropriate processes for discontinuation 
from investigational product or procedures and must discuss with the subject the 
possibilities for continuation of the Schedule of Activities (see Table 1 -1) including 
different options of follow -up (eg, in person, by phone/mail, through family/friends, in 
correspondence/communication with other treating physicians, from the review of 
medical records) and collection of data, including endpoints, adverse events, and 
device -related events and must document this decision in the subject’s medical records.  
Subjects who have discontinued investigational product and/or procedures should not be 
automatically removed from the study.  Whenever safe and feasible, it is imperative that 
subjects remain on -study to ensure safety surveillance and/or collection of outcome 
data.  
Reasons for early removal from protocol -required investigational product(s) or 
procedural a ssessments may include any of the following:  
 Decision by Sponsor  
 Lost to follow -up 
 Death  
 Adverse event  
 Lack of efficacy  
 Subject request  
 Ineligibility determined  
 Protocol deviation  
 Non-compliance  
 Pregnancy  
7.2 Subject Discontinuation/Withdrawal From the Study  
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol -required therapies or procedures, and the subject does not wish to or is 
unable to continue further study participation.  Subject data up to withdrawal of  consent 
will be included in the analysis of the study, and where permitted, publicly available data 
can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study, and mus t document the 
subject’s decision to withdraw in the subject’s medical records.   Subjects who are 
withdrawn or removed from treatment or the study will not be replaced.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 42 of 91 
CONFIDENTIAL    
Refer to the Schedule of Activities ( Table 1 -1) for data to be collected at the time of 
study discontinuation and follow -up and for any further evaluations that need to be 
completed.  
7.2.1  Reasons for Removal From Washout Period, Run -in Period, or 
Invasive Procedures  
Washout, run -in, or invasive procedures do not apply to this study.  
7.2.2  Reasons for Removal From Study  
Reasons for removal of a subject from the study are:  
 Decision by sponsor  
 Withdrawal of consent from study  
 Death  
 Lost to follow -up 
7.3 Lost to Follow -up 
A subject will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a subject fails to return t o the clinic for a required 
study visit:  
 The site must attempt to contact the subject and reschedule the missed visit as soon 
as possible and counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or is able to 
continue in the study.  
 In cases in which the subject is deemed lost to follow -up, the investigator or 
designee must make every effort to regain contact with the subject (where possible, 
3 telephone calls and, if necessar y, a certified letter to the subject’s last known 
mailing address or local equivalent methods).  These contact attempts are to be 
documented in the subject’s medical record.  
 If the subject continues to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  
 For subjects who are lost to follow -up, the investigator should search publicly 
available records where perm itted to ascertain survival status.  This ensures that the 
data set(s) produced as an outcome of the study is/are as comprehensive as 
possible.  
8. Study Assessments and Procedures  
Study procedures and their time points are summarized in the Schedule of Ac tivities 
(see Table 1 -1).  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 43 of 91 
CONFIDENTIAL    
If an enrolled subject is subsequently determined to be ineligible for the study, this must 
be discussed with the sponsor im mediately upon occurrence or awareness to determine 
if the subject is to continue or discontinue study treatment.  
Adherence to the study design requirements, including those specified in the Schedule 
of Activities, is essential and required for study condu ct. 
8.1 General Study Periods  
8.1.1  Screening, Enrollment and/or Randomization  
Informed consent must be obtained before completing any screening procedure.  After 
the subject has signed the informed consent form, the site will register the subject in the 
IRT and screen the subject in order to assess eligibility for participation.  Th e screening 
window is up to 21 days.  
All screening evaluations must be completed and reviewed to confirm that potential 
subjects meet all eligibility criteria.  The investigator will maintain a screening log to 
record details of all subjects screened and t o confirm eligibility or record reasons for 
screening failure, (see Section 5.4) as applicable.  
The baseline period can begin on the same day as th e screening visit or up to 3 weeks 
after the screening visit.  The baseline period begins when the subject has met all the 
screening eligibility criteria and begins baseline study procedures and ends the day 
before the day 1 visit.  The total duration of t he baseline period must be at least 28 days 
and no more than 35 days.  
If a subject has not met all eligibility criteria at the end of the baseline period, the subject 
will be registered as a screen failure.  Subjects who have screen -failed may be 
re-screen ed only once if, in the opinion of the investigator, the reason for the initial 
screen failure has been resolved or is no longer applicable.  Rescreen subjects must first 
be registered as screen failures in IRT and subsequently registered as rescreens.  On ce 
the subject is registered as rescreened, a new screening window will begin.  Subjects 
will retain the same subject identification number assigned at the original screening.  If 
the rescreening period begins more than 45 days after the original signing o f the 
informed consent form, all screening procedures, including informed consent, must be 
repeated.  
8.1.2  Treatment Period  
Visits will occur per the Schedule of Activities ( Table 1 -1).  On -study visits may be 
completed within  7 days.  The date of the first dose of erenumab is defined as day 1.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 44 of 91 
CONFIDENTIAL    
All subsequent doses and study visits will be scheduled based on the day 1 date.  
Erenumab is to be administered b y site staff or by subject self -administration as the last 
procedure of the onsite visits.  All  other doses of erenumab are to be administered by 
subject or designee at a non -investigative site setting (eg, at home), unless a site visit is 
deemed warranted  by the investigator (eg, for changes in erenumab dose) . 
8.1.3  End of Study  
The end of study visit occurs at week 24 (  7 days) or when a subject discontinues from 
the study before the week 24 visit.  All assessments will be performed at the end of 
study visit a s per the Schedule of Activities ( Table 1 -1). 
8.2 General Assessments   
8.2.1  Informed Consent  
All subjects must sign and personally date the IRB/IEC approved informed consent 
before any study -specific procedures are performed.  Key family members must also 
sign an informed consent prior to completing any mGI -I assessments.  
8.2.2  Demographics  
Subject d emographic data collection including sex, age, race, and ethnicity will be 
collected in order to study their possible association with subject s afety and treatment 
effectiveness and satisfaction.  
8.2.3  Medical History  
The Investigator or designee will collect a complete subject medical history that started 
within 120 days prior to screening through baseline.  Medical history will include 
information  on the subject's concurrent medical conditions.  Record all findings on the 
medical history eCRF.  In addition to the medical history, migraine history must date 
back to the original diagnosis. The current severity will be collected for each condition 
that has not resolved.  
Targeted medical history is to be recorded on the appropriate eCRF for neurologic 
medical history, gastrointestinal medical history, and headache and migraine frequency 
medical history.  
8.2.4  Physical Measurements  
The subject’s height (in centimeters) should be measured without shoes.  Weight (in 
kilograms) should be measured without shoes.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 45 of 91 
CONFIDENTIAL    
8.3 Efficacy Assessments  
8.3.1  Treatment Satisfaction Questionnaire for Medication  
The TSQM version 1.4 is a 14 -item instrument designed to measure import ant 
dimensions of patients' experiences with their medication.  It has 4 domains: 
effectiveness, side effects, convenience, and global satisfaction.  Scores range from 0 to 
100 with higher scores indicating greater satisfaction.  The recall period is the l ast 2 to 
3 weeks, or since the medication was last used.  
8.3.2  Migraine Global Impression Item  
The mGI -I is a single item instrument designed to measure improvement/worsening in 
migraine.  The 3 versions of the instrument include the perspective of study subject s, 
key family members, and treating clinicians measured on the following scale: much 
improved; a little improved; no change; a little worse; or much worse.  The recall period 
is the past 7 days.  
8.3.3  Migraine Functional Impact Questionnaire  
The MFIQ version 2.0  is a self -administered 26 -item instrument measuring the impact of 
migraine on broader functioning including 4 domains: Impact on Physical Functioning 
(5 items), Impact on Usual Activities (10 items), Impact on Social Functioning (5 items), 
and Impact on E motional Functioning (5 items).  In addition, there is 1 stand -alone global 
item assessing the overall impact on usual activities.  Subjects respond to items using a 
5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden.  The 
scores will be calculated as the sum of the item responses and the sum will be rescaled 
to a 0 - 100 scale, with higher scores representing greater burden.  The recall period is 
the past 7 days.  
8.3.4  Expectation of Treatment Scale  
The Expectation of Treatment Sc ale (ETS) is a 5-item questionnaire.  Responses 
are scored  on a 5 -point Likert  scale, and subjects’ item  scores  are summed to provide a 
total score  ranging between 5 and 20.  Higher  scores  indicate higher perceived 
expectations.  
8.3.5  Migraine Symptom Severity Scale  
The MSSS is a 7 -item questionnaire that assesses frequency of pain and other 
symptoms associated with migraines.  Responses are as follows: “never,” “rarely,” 
“less  than half the time,” “half the time or more,” and “all or nearly all of the time.”  T he 
responses are given a value from 1 to 3 as follows: Never = 0, Rarely = 1, Less Than 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 46 of 91 
CONFIDENTIAL    
Half the Time = 2, Half the Time or More = 3, and All or Nearly All of the time = 3.  The 
MSSS score is the sum of the 7 items and has a range from 0 to 21.  
8.3.6  Migraine In terictal Burden Scale  
The MIBS -4 measures  interictal migraine -related  burden  with 4 questions that assess  
impairment in work or school, impairment in family and social life, difficulty making plans 
or commitments, and emotional/affective and cognitive dis tress.   Each of the 4 questions 
is responded to using 1 of 6 response categories: “Don’t know/NA” (Score=0), “Never” 
(Score=0), “Rarely” (Score=1), “Some of the time” (Score=2), “Much of the time” 
(Score=3) or “Most or all of the time” (Score=3).  Each que stion is multiplied with its 
score and summed up to produce total score ranges from 0 to 12.  The MIBS -4 total 
scores are categorized into 4 level of interictal burden: None (0), Mild (1 to 2), Moderate 
(3 to 4) and Severe (5 or higher).  
8.3.7  Generalized Anxiet y Disorder Scale  
The GAD -7 is a self -administered 7 -item instrument that uses some of the Diagnostic 
and Statistical Manual (of Mental Disorders) fifth edition (DSM -V) criteria for general 
anxiety disorder (GAD) to identify probable cases of GAD along with  measuring anxiety  
symptom severity.  Responders are asked to rate the frequency of anxiety symptoms in 
the last 2 weeks on a Likert scale ranging from 0 (not at all) to 3 (nearly every day). 
Items are summed to provide a total score.  Score interpretation  is as follows: 1 to 4 
minimal symptoms, 5 to 9 mild symptoms, 10 to 14 moderate symptoms, and 15 to 21 
severe symptoms.  Changes of 5 points or more are clinically meaningful.   
8.3.8  Patient Health Questionnaire  
The PHQ -9 is a self -administered questionnaire, w idely used for diagnosis and severity 
assessment of depression in primary care settings.  The PHQ -9 is a 9 -question, 
self-administered instrument for screening, diagnosing, monitoring, and measuring the 
severity of depression.  It incorporates Diagnostic an d Statistical Manual (of Mental 
Disorders) fourth edition (DSM -IV) depression diagnostic criteria with other leading major 
depressive symptoms into a brief self -report tool.  The tool rates the frequency of the 
symptoms which factors into the scoring sever ity index.  The PHQ -9 scores each of the 
9 DSM -IV criteria as “0” (not at all) to “3” (nearly every day).  The score is calculated as 
the sum of the item responses and corresponds to 1 of the 5 severity categories: 
Minimal or None = 0 to 4, Mild = 5 to 9, Moderate = 10 to 14, Moderately Severe = 
15 to 19, and Severe = 20 to 27.  Question 9 on the PHQ -9 screens for the presence 
and duration of suicide ideation.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 47 of 91 
CONFIDENTIAL    
8.3.9  Electronic Diary  
The eDiary will collect migraine -related parameters at home, including the follow ing:  
 presence or absence of headache and whether the headache is a migraine  
 presence or absence of aura  
 use of acute headache medications and whether the acute headache medication is a 
triptan  
 worst headache severity  
At the start of the baseline perio d, which may coincide with the screening visit, the  site 
staff will instruct the subject on eDiary use (eg, accessing the application, navigating 
screens, transmitting data, contacting the help desk for technical assistance).  The 
subject will be instructe d to interact with the eDiary as per the Schedule of Activities 
(Table 1 -1).  At the day 1 visit, the investigator will use the subject’s eDiary to re view all 
data entered during the baseline period and confirm the relevant inclusion and exclusion 
criteria.  
8.4 Safety Assessments  
Planned time points for all safety assessments are listed in the Schedule of Activities 
(Table 1 -1). 
8.4.1  Clinical Laboratory Assessments  
Refer to Section 11.2 for the list of clinical laboratory tests to be performed and to the 
Schedule of Activities ( Table 1 -1) for the timing and frequency.  
All protocol -required laboratory assessments, as defined in Section 11.2, must be 
conducted in accor dance with the laboratory manual and the Schedule of Activities 
(Table 1 -1).  Note: the only protocol -required laboratory assessment is the urine 
pregnancy test for women of childbearing potential.  
8.4.2  Adverse Events and Serious Adverse Events   
The method of recording, evaluating, and assessing causality of adverse events, 
adverse  device events, and serious adverse events and the procedures for 
completing and transmitting serious adverse event reports are provided in 
Section  11.4.   
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 48 of 91 
CONFIDENTIAL    
8.4.2.1  Time Period and Frequency for Collecting and Reporting Safety 
Event Information  
8.4.2.1.1  Adverse Events  
The adverse event grading scale to be used for this study will be the Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.03 and is describe d in 
Section 11.4. 
The investigator is responsible for ensuring that all adverse events observed by the 
investigator or reported by the subject that occur after first dose of investigational 
product  through th e end of study  are reported using the Events eCRF.  
8.4.2.1.2  Serious Adverse Events  
The investigator is responsible for ensuring that all serious adverse events observed by 
the investigator or reported by the subject that occur after signing of the informed 
consent through end of study  are reported using the Events eCRF.  
All serious adverse events will be collected, recorded and reported to the sponsor or 
designee within 24  hours of the investigator’s awareness of the event, as indicated in 
Section 11.4.  The investigator will submit any updated serious adverse event data to the 
sponsor within 24  hours of it being available.  
Since the criteria for the CTCAE grading scale differs from the regulatory criteria for 
serious adverse events,  if adverse events correspond to grade  4 CTCAE toxicity 
grading scale criteria (eg, laboratory abnormality reported as grade  4 without 
manifestation of life -threatening status), it will be  left to the investigator’s judgment 
to also report these abnormalities as serious adverse events.  Laboratory abnormality 
with clinical significance will be reported as an adverse event .  If an adverse event 
associated with a laboratory abnormal ity meets the criteria of a serious event, it 
will be reported as a serious adverse event based upon the investigator’s 
judgment.  For any adverse event that applies to this situation, comprehensive 
documentation of the event’s severity must be recorded in  the subject medical 
records.  
8.4.2.1.3  Serious Adverse Events After the Protocol -required Reporting 
Period  
After End of study, there  is no requirement to actively monitor study subjects after the 
study has ended with regards to study subjects treated by the investigator.  
However, if the investigator becomes aware of serious adverse events  suspected to 
be related to investigational product, then these serious adverse events will be 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 49 of 91 
CONFIDENTIAL    
reported to Amgen within  24 hours following the  investigator’s awareness of the 
event .  Per local requirements in some countries, investigators are  required to 
report serious adverse events that they become aware of  after end of study.  If 
serious adverse events are reported, the investigator is to report  them to Amgen 
within 24  hours following the investigator’s awareness of the event .  Per local 
requirements in some countries, investigators are required to report serious adverse 
events that they become aware of aft er end of study.  If serious adverse events are 
reported, the investigator is to report them to Amgen within 24 hours following the 
investigator’s awareness of the event .   
Serious adverse events reported outside of the protocol -required reporting period w ill be 
captured within the safety database as clinical trial cases and handled accordingly based 
on relationship to investigational product.  If further safety related data is needed to 
fulfill any regulatory reporting requirements for a reportable event, then additional 
information may need to be collected from the subject’s records after the subject 
ends the study.  
The method of recording, evaluating, and assessing causality of adverse events, 
adverse device effects,  and serious adverse events and the pro cedures for completing 
and transmitting serious adverse event reports are provided in Section 11.4. 
8.4.2.2  Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to introduce bias when detecting adverse events and/or serious 
adverse events.  Open -ended and non -leadin g verbal questioning of the subject is the 
preferred method to inquire about adverse event  occurrence.  
8.4.2.3  Follow -up of Adverse Events and Serious Adverse Events  
After the initial adverse event/serious adverse event report, the investigator is required to 
proactively follow each subject at subsequent visits/contacts.  All adverse events and 
serious adverse events will be followed until resolution, stabilization, until the event is 
otherwise explained, or the subject is lost to follow -up (as defined in Section 7.3).  
Further information on follow -up procedures is given in Section 11.4. 
All new information for previously reported serious adverse events must be sent to 
Amgen within 24 hours following awareness of the new information.  If specifically 
requested, the investiga tor may need to provide additional follow -up information, such as 
discharge summaries, medical records, or extracts from the medical records.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 50 of 91 
CONFIDENTIAL    
Information provided about the serious adverse event must be consistent with that 
recorded on the Events CRF.  
8.4.2.4  Regulatory Reporting Requirements for Serious Adverse Events  
If subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, this information must be submitted to Amgen.  
Prompt notification by the investigator to the s ponsor of serious adverse events is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects and the safety of a study treatment under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study treatment under clinical 
investigation.  The sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory auth ority, IRBs/IECs, and investigators.  
Individual safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and sponsor policy and forwarded 
to investigators as necessary.  
An investigator wh o receives an individual safety report describing a serious adverse 
event or other specific safety information (eg, summary or listing of serious adverse 
events) from the sponsor will file it along with the Investigator’s Brochure and will notify 
the IRB/I EC, if appropriate according to local requirements.  
8.4.2.5  Safety Monitoring Plan  
Subject safety will be routinely monitored as defined in Amgen’s safety surveillance and 
signal management processes.  
8.4.2.6  Pregnancy and Lactation  
A urine pregnancy test should be comple ted at screening and within 7 days of initiation 
of investigational product for females of childbearing potential.  
Note:  Females who have undergone a bilateral tubal ligation/occlusion should have 
pregnancy testing per protocol requirements.  (If a female  subject, or the partner of a 
male subject, becomes pregnant it must be reported on the Pregnancy Notification 
Form  (Figure 11 -2).  Refer to Section 11.5 for contraceptive requirements.   
Additional pregnancy testi ng should be performed at intervals of every 12 weeks 
(+/- 7 days) during treatment with protocol -required therapies and at the end of study.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 51 of 91 
CONFIDENTIAL    
Additional on -treatment pregnancy testing may be performed at the investigator’s 
discretion,  if there is suspicion that a female subject is pregnant,  or as required per local 
laws and regulations.  
Details of all pregnancies and/or lactation in female subjects  will be collected after the 
start of study treatment and unt il 16 weeks after the last d ose of investigational product . 
If a pregnancy is reported, the investigator is to inform Amgen within 24 hours of learning 
of the pregnancy and/or lactation and is to follow the procedures outlined in 
Section  11.5.  Amgen Global Patient Safety will follow -up with the investigator regarding 
additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death , stillbirth, 
congenital anomalies, ectopic pregnancy) are considered serious adverse events.  
Further details regarding pregnancy and lactation are provided in Section 11.5. 
8.4.2.7  Adverse Device Effects  
In order to fulfill regulatory reporting obligations worldwide, the investigator is 
responsible for the detection and documentation of any adverse device effects that occur 
during the study with such devices.  
An adverse device effect is any adverse event related to the use of a combination 
product or medical device.  Adverse device effects include adverse events resulting from 
insufficient or inadequate instructions for use, adverse events resulting from any 
malfunction of the device, or adverse events res ulting from use error or from intentional 
misuse of the device.  
All adverse device effects are to be reported as adverse events following the same 
reporting periods and procedures.  
Product complaints are described in Section 6.1.6 . 
Further details regarding adverse device effects can be found in Section 11.4. 
8.5 Optional Substudy: Qualitative Interviews  
8.5.1  Substudy Background and Rationale  
Qualitative interviews enable access to qualitative aspects of experiences of clinical trial 
participants to supplement the quantitative data collected as part of the study.  For 
example, treatment satisfaction can be assessed to understand which aspects of the 
treatment are valued by subjects such as symptom benefit, delivery method, and safety 
and tolerability.   Interviewing clinical trial participants at the start and end of the 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 52 of 91 
CONFIDENTIAL    
treatment period can also help identify benefits most relevant and meaningful to patients.  
This can also complement and help interpret the quantitative data collected using COA 
instrum ents in the clinical trial.   
Regulatory agencies are showing increasing interest in understanding patients’ 
experiences of the risk -benefit related to new interventions being tested in clinical trials 
(FDA, 2017 ).  Qualitative interviews at the start and end of clinical trials help to 
understand the patient experience of the treatment in the trial setting: their experience of 
the convenience of treatment, changes they perceive as result of treatments, and 
informal assessments of trade -offs on benefit and r isks they perceive about the 
treatment.  
8.5.2  Research Question and Objectives of the Qualitative Interview 
Substudy  
The aim of this substudy is to collect qualitative data to assess the experience of 
treatment from a subset of adults who have participated in S tudy 20190389, their 
clinicians, and key family members to provide a more in -depth understanding of patients’ 
experience with migraine and the impact of migraine, including perception of symptoms 
and burden of disease.  The objectives are to elicit the sub ject’s, clinician’s, and family 
member’s perceptions of migraine, associated symptoms, and symptom impact/burden 
and interference on the subject’s life, subject perceptions of meaningful changes in 
experience of migraine, and to explore subject experience with treatment administration.  
8.5.3  Substudy Design  
Qualitative interviews will be conducted with approximately 20 subjects, their clinicians, 
and key family members (collectively referred to as “participants”) who opt in to this 
optional substudy.  The substu dy sample size is based on a convenience sample to 
allow for sufficient numbers of EM and CM subjects enrolled.  Best efforts will be made 
to ensure that the sample includes subjects with diverse demographic characteristics 
from the pool of trial subjects.   
Interviews will be conducted at study entry, within 7 days of the first investigational 
product dose (Day 1), and at study exit, within 7 days of the week 24 visit or within 
approximately 14 days of the early termination visit.  If possible, within 7 day s from early 
termination notification will be targeted .  No protocol deviation will occur if these 
interviews are conducted outside of these timeframes.    
Note: Subjects must have received a first dose of investigational product before the entry 
interview is conducted.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 53 of 91 
CONFIDENTIAL    
8.5.4  Summary of Substudy Participation Criteria  
Study subjects must meet the following criteria to be considered for enrollment into the 
substudy:  
1) Be enrolled in Study 20190389;  
2) Have provided supplementary informed consent to participate i n the substudy;  
3) Be willing and able to participate in 2 telephone interviews lasting approximately 
1 hour each;  
4) Be able to read, understand, and speak English sufficiently to participate in the 
interviews;  
5) Be willing to be audio -recorded during  the interview sessions.  
The key family member should be a family member/caregiver of an enrolled patient and 
should be the person in the subject’s life that s/he interacts with the most on a day -to-
day basis.   Key family members must meet the following cr iteria to be considered for 
enrollment into the substudy:  
1) Should have a deep understanding of the impact migraine has on the subject.  They 
should also be able to provide their perspective of change in the subject’s migraines 
over time.  The person the subject chooses to nominate can be anyone such as a 
spouse, daughter or son, parent, sibling, or other relative or the person the subject is in a 
de facto relationship with.  
2) Have provided informed consent to participate in the substudy;  
3) Be willing a nd able to participate in 2 telephone interviews lasting approximately 
1 hour each;  
4) Be able to read, understand, and speak English sufficiently to participate in the 
interviews;  
5) Be willing to be audio -recorded during the interview sessions.  
Clinicians must meet the following criteria to be considered for enrollment into the 
substudy:  
1) Be a US -licensed and practicing healthcare practitioner (HCP) at the clinical site 
(eg, neurologist, headache specialist, primary care physician, nurse practi tioner, 
physician assistant) currently treating the subject on Study 20190389;  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 54 of 91 
CONFIDENTIAL    
2) Be willing and able to participate in 2 telephone interviews lasting approximately 
1 hour each;  
3) Be able to read, understand, and speak English sufficiently to participate  in the 
interviews;  
4) Be willing to be audio -recorded during the interview sessions.  
Meeting any of the following criteria will exclude a subject, key family member, or 
clinician from enrollment into the substudy:  
1) Expected to be unable to complete en try interview within 7 days from first 
investigational product dose;  
2) Expected to be unable to complete exit interview within 7 days prior to week 24 visit or 
within approximately 14 days post early termination visit;  
3) Has any clinically relevant medi cal or psychiatric condition that, in the opinion of the 
investigator and/or study coordinator, would interfere with the completion of the substudy 
activities.  This includes but is not limited to language, speech, hearing or cognitive 
disorders that could  impact a participant’s ability to participate in an interview -based 
discussion.  
8.5.5  Substudy Duration and Substudy Procedures  
Subjects, clinicians, and key family members will participate in 2 telephone interviews, 
lasting approximately 1 hour each.  Entry interviews will be conducted within 7 days from 
first investigational product dose (day 1); exit interviews will be conducted  within 7 days 
prior to week 24 visit or within approximately 14 days post early termination visit.  If 
possible, within 7 days from early termination notification will be targeted .  No protocol 
deviation will occur if these interviews are conducted outsid e of these timeframes.  
Subjects enrolled in Study 20190389 will be approached by clinic  staff for recruitment 
and possible enrollment into this substudy.  
At participating sites, subjects will be provided an option to opt -in to the qualitative 
interview s ubstudy and be provided with additional information about the substudy either 
at time of screening for the main study or after enrollment and successful dosing with 
investigational product, depending on site preference.  Clinical site staff will explain th e 
substudy objectives and procedures to the subject and their selected key family member 
and obtain a supplementary written informed consent from each participant.  Each 
subject and key family member will sign 2 copies of the consent form.  Sites will send  a 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 55 of 91 
CONFIDENTIAL    
wet-ink version of the informed consent to Evidera, the third -party supplier who is 
performing the substudy, and will retain a copy of the signed informed consent for their 
study records.  Clinic site staff will provide Evidera contact information for e ach 
participant enrolled in the substudy and Evidera will subsequently contact each 
participant to schedule interviews.  
Once consent has been obtained, the subject ID and site details can be communicated 
by the site to the interview scheduler from Evidera along with potential dates for the day 
1 and week 24 visits.  The interview scheduler will obtain contact information and 
schedule tentative dates and times for the interviews with the subject, clinician, and key 
family member.  Evidera will confirm with t he site that the subject has completed study 
procedures for the day 1 and week 24 visits before confirming the interview dates and 
times of the interviews to ensure compliance to the substudy protocol.  
Evidera staff, who are trained and experienced in qua litative data collection, will conduct 
telephone interviews using a semi -structured interview guide.  Participants will be 
interviewed about the subject’s pre -treatment status, any perceived changes during the 
study, and the meaningfulness of the changes e xperienced.  During the interviews, 
interviewers will ask participants for specific examples to qualitatively illustrate the 
subjects’ experience.  
Participants will be specifically asked about the subject’s functional abilities during and 
between migraine  attacks after the start of the study; ie, perceptions of migraine, 
associated symptoms, and symptom impact/burden and interference on the subject’s 
life; perceptions of meaningful changes in experience of migraine; and experience with 
treatment administra tion. 
After open -ended questions, if participants do not mention concepts associated with the 
domains of the COA instrument in the clinical trial, the interviewer will specifically probe 
about those concepts.  The interviewers will also explore what aspect s of improvement 
or worsening of the subject’s migraine (eg, frequency, severity, and duration) drove the 
changes, as well as the meaningfulness of change/no change reported by the subject.  
8.5.6  Variables  
8.5.6.1  Substudy Outcome Variable(s)  
Qualitative data on chang es resulting from treatment received in the open -label 
treatment period will be collected via telephone interview.  Concepts that emerge from 
the qualitative interviews in relation to migraine impact, treatment efficacy, and migraine 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 56 of 91 
CONFIDENTIAL    
experience will be the  outcome.  Data will be analyzed to achieve the study objectives, 
using qualitative data analysis software (ie, ATLAS.ti).  
8.5.6.2  Exposure Variable(s)  
Subjects will be started on the 70 mg dose of erenumab with provider discretion for dose 
optimization.  Dose op timization will allow patients to remain on 70 mg, increase the 
dose from 70 to 140 mg and if needed decrease the dose back down from 140 to 70 mg.  
After week 12, all subjects are highly recommended to remain on the week 12 erenumab 
dose for the rest of t he study. Dose changes are permitted at the investigator’s 
discretion, but are not recommended unless medically necessary.  
8.5.7  Substudy Data Analysis  
Audio recordings from the interviews will be transcribed for qualitative analyses.  Evidera 
will develop a sep arate data analysis plan that will detail how the qualitative data will be 
analyzed.  The analyses of interview data will help to illustrate subjects’ perceptions of 
meaningful change or difference, migraine functional impacts, and treatment efficacy or 
benefit.  Subjects will be grouped by migraine type, and other exploratory subgroups 
may be determined based on the characteristics of the final sample.  The qualitative 
report will discuss perceived treatment benefit and changes, if any, in relation to 
entry-interview discussion of the functional impacts of migraine.  
A qualitative content analysis approach will be used to analyze data collected from 
qualitative interviews using coding dictionaries and ATLAS.ti qualitative data analysis 
software.  The cleane d transcripts will be entered into ATLAS.ti qualitative analysis 
software version 7.0 or higher ( Friese and Ringmayr, 2013 ).  Qualitative data coded in 
ATLAS.ti can be systematically organized into analysis outputs.  ATLAS.ti software is 
designed to facili tate the storage, coding, and retrieval of qualitative data.   
Coding will be an iterative process that marks the beginning of the qualitative analysis 
process.  Concept codes will be used to capture symptoms or impacts of the disease 
most important and re levant to participants.  Qualitative data will be coded according to 
the coding dictionary as outlined in the analysis plan.  The initial coding dictionary will be 
based on the structure of the main themes and content of the discussion guide to allow 
the text data to be coded with key concepts codes.  The coding dictionary will be 
iteratively updated with emerging themes and concepts from discussions.   
Evidera proposes to conduct longitudinal qualitative research analyses ( Calman et al, 
2013 ; Saldana, 2003 ), which is distinguished from a traditional qualitative approach by 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 57 of 91 
CONFIDENTIAL    
the fact that the key focus of analysis is on how and why the subject experiences/ 
perceptions change over time.  This innovative approach will be used to characterize 
changes in subjects ’ perceptions and experiences over time, particularly in concepts the 
subjects perceive as most important.  
A list of each key concept identified at analysis of entry interviews will be provided to 
interviewers ahead of the follow -up interviews, so that th ese may be probed at the 
follow -up interviews.  For each concept, a category will be assigned to show changes in 
concepts that occurred between the 2 time points (newly emerged, not changed/stable, 
improved, worsened, not experienced anymore, and missing) in the concept tracker.  
Each of the concepts probed during the follow -up interviews will be categorized and 
compared to the entry interview.  An analysis will then be conducted on the data from 
groups of participants to document the changes observed over time.  
All analysis and reporting will be conducted by Evidera staff with experience in 
qualitative research.   
Subject characteristics collected in the clinical trial will be summarized for describing the 
sample.  Descriptive statistics (eg, n, mean, SD, and/or frequency) will be used to 
characterize the sample in terms of questionnaire data, sociodemographic, and clinical 
characteristics.  
The results of this sub -study will be reported separately from the main study.  
8.5.8  Collection of Safety Information and Pr oduct Complaints  
There will be no substudy -specific safety database for collection, recording, and 
reporting of adverse events reported during the conduct of the substudy.  All safety data 
collection, recording, and reporting will be performed through the  parent study and will 
follow the detailed procedures outlined in Study Protocol 20190389.  Adverse events, 
serious adverse events, or product complaints reported during the conduct of an 
interview will be reported to Amgen and to investigational sites wit hin 1 business day of 
awareness.  
8.5.8.1  Definition of Safety Events  
Refer to Section 11.4 for definition of safety events.  
8.5.8.2  Safety Reporting Requirements  
The clinical site investigator is responsible for ensuring that safety events (adverse 
events, product complaints, and other safety findings) are reported in accordance with 
Amgen’s Study 20190389 protocol.  Evidera will report any adverse events to the clinical 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 58 of 91 
CONFIDENTIAL    
site and Amgen within 1 business day of awareness; the si te investigator will be 
responsible for reconciling the reporting to Amgen.  
Safety events must be submitted as individual case safety reports to Amgen via the 
applicable Amgen Safety Reporting Form (paper or electronic form) which will be the 
responsibilit y of the subject’s clinic site in accordance with the Study 20190389 protocol.  
9. Statistical Considerations  
9.1 Statistical Hypotheses  
The study is descriptive in nature without a comparator arm, and as such no formal 
statistical hypothesis is defined.  
9.2 Sample Size Determination  
The total sample size of approximately 322 subjects (effective sample size of 
289 assuming 10% dropout at week 24) is driven by the precision of the proportion 
estimates for the binary secondary endpoints, which targets a half -width of 95% 
confidence intervals (CIs) around 5%. The half -width of the 95% CI will be the widest 
when the estimated percentage is 50% given a fixed sample size and will become 
narrower if the percentage moves further away from 50% (see  Table 9 -1).   
Table 9-1.  Half -width of 95% CI for Various Estimated Percentages With Effective 
Sample Size of 289 Subjects  
Percentage  
estimate  Half-width of 95% CI  
with ef fective sample 
size = 289  
50% 5.8%  
60% 5.6%  
70% 5.3%  
80% 4.6%  
 
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 59 of 91 
CONFIDENTIAL    
9.3 Populations for Analysis  
The following populations are defined:  
Population  Description  
Full Analysis Set  The full analysis set (FAS) consists of all subjects enrolled 
in the study.  Analysis of disposition, demographic and 
baseline characteristics, and important protocol deviations 
will utilize the FAS.  
Efficacy Analysis Set  The respective efficacy analysis set consists of a subset of 
subjects from FAS who receive at least 1 dose of  
investigational product and have a baseline value and at 
least 1 post baseline value for the endpoint of interest. 
Analysis of the primary and secondary efficacy endpoints 
(except for the global impression Patient Reported 
Outcomes [PRO] endpoints) will u tilize the respective 
efficacy analysis set.  
Global Impression PRO 
Analysis Set  The global impression PRO analysis set consists of a 
subset of subjects from FAS who receive at least 1 dose of 
investigational product and have at least 1 post baseline 
value  for the global impression PRO endpoints of interest . 
Analysis of each of the 3 global impression PRO endpoints 
will utilize this analysis set.  
Safety Analysis Set  The safety analysis set (SAS) will consist of a subset of 
subjects from FAS who received at  least 1 dose of 
investigational product. Analysis of safety endpoints and 
summary of investigational product administration will 
utilize the safety analysis set.  
 
9.3.1  Covariates  
All model -adjusted analyses of primary and secondary efficacy endpoints will include the 
corresponding baseline value for the endpoint being analyzed, if applicable, and 
baseline MMD.  
9.3.2  Subgroups  
The primary and secondary endpoints will be analyzed in th e following subgroups:  
 Whether remained on standard of care migraine preventive treatment throughout the 
study (yes vs no)  
 Migraine type (EM vs CM) based on eDiary collection during baseline  
The subgroups will be re -examined for appropriateness and may be re-categorized (due 
to small sample size, for example, if there are < 10% of subjects within a subgroup) 
before final analysis.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 60 of 91 
CONFIDENTIAL    
9.4 Statistical Analyses  
The statistical analysis plan will be developed and finalized before database lock.  Below 
is a summary  of the timing and methods for the planned statistical analyses.  
9.4.1  Planned Analyses  
9.4.1.1  Interim Analysis and Early Stopping Guidelines  
Not applicable.  
9.4.1.2  Primary Analysis  
Not applicable.  
9.4.1.3  Final Analysis  
The final analysis will be conducted when all enrolled subj ects have completed the 
week  24/EOS visit  and the data have been entered, cleaned, and locked . 
9.4.2  Methods of Analyses  
9.4.2.1  General Considerations  
Summary statistics will be computed at each timepoint of interest.  For continuous 
endpoints, the following desc riptive statistics will be computed: number of observations, 
means, standard deviations, standard errors, medians, first and third quartiles, 
minimums and maximums.  For categorical endpoints, the summaries will contain the 
number and percentage of subject s in each category.  
Due to lack of a control arm, all analyses should be considered as descriptive in nature.  
Data on any endpoints collected after treatment discontinuation due to lack of efficacy or 
adverse event will be defined based on the worst observed value (for continuous 
endpoints) or non -response (for binary endpoints) using a composite strategy.  Data 
collected after treatment discontinuation due to other reasons will be censored based on 
a hypothetical strategy and not be used in efficacy analyses as described in 
Section  9.4.2.2 . 
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 61 of 91 
CONFIDENTIAL    
9.4.2.2  Efficacy Analyses  
 
Endpoint/ 
Estimand  Statistical Analysis Methods  
Primary  In the event of IP discontinuation due to lack of efficacy or adverse 
event, the TSQM overall satisfaction scale score  after treatment 
discontinuation will be defined as the worst postbaseline value 
observed up to IP discontinuation (inclusive).  Any TSQM data 
collected after treatment discontinuation due to other reasons will be 
censored and not included in the analysis.   
The primary endpoint will be analyzed using a repeated measures 
mixed effects model, including baseline TSQM overall satisfaction 
scale score, visit, the prevailing erenumab dose from week  12 
onwards, and baseline MMD based on observed data .  The mean 
change from baseline in TSQM overall satisfaction scale score at 
week 24 will be estimated from the least -squares mean (LSM) of the 
mixed effects model, and the corresponding 95% CI will be provided.  
The nominal p -value will be reported by comparing the mea n change 
from baseline in TSQM overall satisfaction scale score at week 24 to 
zero with a two -sided 5%  significance level.  
Secondary  In the event of IP discontinuation due to lack of efficacy or adverse 
event, the binary secondary endpoint after IP discon tinuation will be 
classified as not achieving overall satisfaction or global impression on 
improvement; and the continuous MFIQ domain scores after treatment 
discontinuation will be defined as the worst postbaseline value 
observed before treatment disconti nuation.  Data collected after IP 
discontinuation due to other reasons will be censored and not included 
in the analysis.   
A generalized linear mixed effects model with the appropriate link 
function will be used to analyze each secondary endpoint based on  
observed data .  The model will include the corresponding baseline 
value for the endpoint being analyzed (except for the global 
impression endpoints), visit, the prevailing erenumab dose from week 
12 onwards, and baseline MMD.   
For binary secondary endpoi nts, logit link function will be used, and 
the proportions and the corresponding 95% CI at week 24 will be 
estimated from the LSM (with inverse link function) of the mixed 
effects model.  
For the continuous MFIQ domain score endpoints, identity link functi on 
will be used, and mean change from baseline in each domain score at 
week 24 with the corresponding 95% CI will be estimated from the 
LSM of the mixed effects model, and p -values comparing with zero at 
a 2-sided 5% significance level will be reported.  
Exploratory  Will be described in the statistical analysis plan (SAP) finalized before 
database lock  
 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 62 of 91 
CONFIDENTIAL    
9.4.2.3  Safety Analyses  
All safety analyses will be performed based on all subjects in the Safety Analysis Set, 
both overall and separately by migraine prevent ion therapy standard of care status 
(continuation vs discontinuation).  
9.4.2.3.1  Adverse Events  
The Medical Dictionary for Regulatory Activities (MedDRA) will be used to code all 
adverse events.  
Subject incidence of all treatment -emergent adverse events will be tabulated by system 
organ class and preferred term.  Tables of fatal adverse events, serious adverse events, 
adverse events leading to discontinuation from investigational product and 
treatment -emergent adverse events of interest will also be provided.   Subject incidence 
of device -related events, if applicable, will be tabulated by system organ class and 
preferred term.  
9.4.2.3.2  Exposure to Investigational Product  
The number and percentage of subjects with dose change, reason for dose change and 
duration of expo sure to investigational product in days will be summarized over time.  
9.4.2.3.3  Exposure to Concomitant Medication  
Number and proportion of subjects receiving migraine preventive medications will be 
summarized by medication category.  Number and proportion of subjects who 
discontinue standard of care migraine prevention therapy will also be 
summarized .   
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 63 of 91 
CONFIDENTIAL    
10. References  
Antonaci F, Dumitrache C, De Cillis I, et al. A review of current European treatment 
guidelines for migraine. J Headache Pain. 2010;11(1):13 -19.  
Calman L, Brunton L, Molassiotis A. Developing longitudinal qualitative designs: lessons 
learned and recommendations for health services research. BMC Med Res Methodol. 
2013;13:14.  
Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized tr ial of 
erenumab for episodic migraine.  Cephalalgia.  2018;38(6):1026 -1037.  
Erenumab Investigator’s Brochure. Thousand Oaks, CA.  Amgen Inc.  
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report 
of an EFNS task force.   Eur J Neurol.  2006;13(6):560 -572.  
Food and Drug Administration (FDA).  Plan for Issuance of Patient -Focused Drug 
Development Guidance. 2017. Available at: 
https://www.fda.gov/media/105979/download.  
Friese S, Ringmayr T. ATLAS.ti 7 User Guide and Refer ence.  Berlin:  ATLAS.ti 
Scientific Software Development GmBH; 2013.  
Goadsby PJ & Evers S.  International Classification of Headache Disorders – 
ICHD -4 alpha.  Cephalalgia.  2020;40(9):887 -888.  
Goadsby PJ, Holland PR, Martins -Oliveira M, Hoffmann J, Scha nkin C, Akerman S.  
Pathophysiology of Migraine:  A Disorder of Sensory Processing.  Physiol Rev.  
2017;97(2):553 -622.  
Goadsby PJ, Lipton RB, Ferrari MD.  Migraine —current understanding and treatment.  
N Engl J Med.  2002;346(4):257 -270.  
Headache Classif ication Committee of the International Headache Society (IHS).  The 
International Classification of Headache Disorders, 3rd ed (ICHD -3).  Cephalalgia.  
2018;38(1):1 -211.  
Headache: The Journal of Head and Face Pain , 2018.  The American Headache Society 
Position Statement On Integrating New Migraine Treatments Into Clinical Practice.  
Katsarava Z, Buse DC, Manack AN, Lipton RB.  Defining the differences between 
episodic migraine and chronic migraine.  Curr Pain Headache Rep.  2012;16:86 -92.  
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF.  AMPP Advisory 
Group: migraine prevalence, disease burden, and the need for preventive therapy.  
Neurology.  2007;68:343 -349.  
Robbins MS, Lipton RB. The epidemiology of primary headache disorders. Semin 
Neuro l. 2010;30(2):107 -119.  
Saldana J. Longitudinal Qualitative Research: Analyzing Change Through Time. 
AltaMira Press, US; 2003.  
Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight 
project. J Headache Pain. 2010;11(4):289 -299.  
Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of 
episodic migraine: a randomised, doub le-blind, placebo -controlled, phase 2 trial. Lancet 
Neurol. 2016;15(4):382 -390.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 64 of 91 
CONFIDENTIAL    
Tajti J, Uddman R, Möller S, Sundler F, Edvinsson L. Messenger molecules and 
receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76:176 -183.  
Tepper S, Ash ina M, Reuter U, et al. Safety and efficacy of erenumab for preventive 
treatment of chronic migraine: a randomised, double -blind, placebo -controlled phase 2 
trial. Lancet Neurol. 2017;16(6):425 -434. 
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 65 of 91 
CONFIDENTIAL    
11. Appendices  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 66 of 91 
CONFIDENTIAL    
11.1 Appendix 1.  List of Abbreviations  
 
Abbreviation  Explanation  
ACE angiotensin -converting enzyme  
AI autoinjector  
CBT cognitive behavioral therapy  
CFR U.S. Code of Federal Regulations  
CGRP  calcitonin gene related peptide  
COA  clinical outcomes assessment  
CM chronic migraine  
CRF case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
DILI drug induced liver injury  
DSM  Diagnostic  and Statistical  Manual  of Mental Disorders  
eCRF  Electronic Case Report Form  
eDiary  electronic diary  
EDC  electronic data capture  
EM episodic migraine  
EOS  end of study  
ETS Expectation of Treatment Scale  
FAS full analysis set  
FSH follicle stimulating hormone  
GAD  general anxiety disorder  
GAD -7 General Anxiety Disorder scale  
GCP  Good Clinical Practice  
HCP  healthcare practitioner  
HRT hormone replacement therapy  
ICF informed consent form  
ICH International Council for Harmonisation  
ICHD  International Headache Classification Disorders  
IEC Independent Ethics Committee  
IHS International Headache Society  
IP investigational product  
IRB Institutional Review Board  
IRT interactive response technology  
LSM least -squares mean  
MedDRA  Medical Dictionary for Regulatory Activities  
MFIQ  Migraine Functional Impact Questionnaire  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 67 of 91 
CONFIDENTIAL    
mGI-I Migraine Global Impression Item  
MIBS -4 Migraine Interictal Burden Scale  
MMD  monthly migraine days  
MSSS  Migraine Symptom Severity Scale  
NCT National Clinical Trials  
QTL quality tolerance limit parameter  
PHQ -9 Patient Health Questionnaire  
PRO  patient reported outcome  
Q4W  every 4 weeks  
QM once monthly  
SAP statistical analysis plan  
SAS safety analysis set  
SC subcutaneous  
TSQM -14 Treatment Satisfaction Questionnaire for Medication  
US United States  
 
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 68 of 91 
CONFIDENTIAL    
11.2 Appendix 2.  Clinical Laboratory Tests  
A urine pregnancy test will be performed locally for women of childbearing potential as 
specified in the Schedule of Activities ( Table 1 -1).  
Protocol -specific requirements for inclusion or exclusion of subjects are detailed in 
Sections 5.1 to 5.2 of the protocol.  
Additional tests may be performed at any time during the study as determined necessary 
by the investigator or required by local regulations.  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 69 of 91 
CONFIDENTIAL    
11.3 Appendix 3.  Study Governance  Considerations  
Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for Internat ional Organizations of Medical 
Sciences International Ethical Guidelines  
 Applicable International Council for Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines  
 Applicable ICH laws and regulations  
The protocol, protocol amendments, informed consen t form, Investigator’s Brochure, and 
other relevant documents (eg, subject recruitment advertisements) must be submitted to 
an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)  by the 
investigator and reviewed and approved by the IRB/IEC .  A copy of the written approval 
of the protocol and informed consent form must be received by Amgen before 
recruitment of subjects into the study and shipment of Amgen investigational product.  
Amgen may amend the protocol at any time.  The investigator mu st submit and, where 
necessary, obtain approval from the IRB/IEC  for all subsequent protocol amendments 
and changes to the informed consent document.  The investigator must send a copy of 
the approval letter from the IRB/IEC  and amended protocol Investigat or’s Signature 
page to Amgen prior to implementation of the protocol amendment at their site.  
The investigator will be responsible for the following:  
 Providing written summaries of the status of the study to the IRB/IEC  annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC  
 Obtaining annual IRB/IEC  approval/renewal throughout the duration of the study.  
Copies of the investigator’s reports and the IRB/IEC  continuance of approval must be 
sent to Amgen  
 Notifying the IRB/IEC  of serious adverse events occurring at the site, deviations from 
the protocol or other adverse event reports received from Amgen, in accordance with 
local procedures  
 Overall conduct of the stu dy at the site and adherence to requirements of Title  21 of 
the U.S. Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC , and all 
other applicable local regulations  
 
 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 70 of 91 
CONFIDENTIAL    
Recruitment Procedures  
Site staff will identify potential subjects from their existing patient population or may seek 
referral patients through existing professional networks or other community sources such  
as patient advocacy groups. All patient facing materials must be reviewed/approved by 
the sponsor (Amgen Inc.) and the local IR B/IEC.  
Informed Consent Process  
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the sample 
informed consent form are to be communicated formally in  writing from the Amgen  Trial 
Manager to the investigator.  The written informed consent form is to be prepared in the 
language(s) of the potential participant population.  
The investigator or his/her delegated representative will explain to the participant  (ie, 
study subject or key family member) the aims, methods, anticipated benefits, and 
potential hazards of the study and optional sub -study before any protocol -specific 
screening procedures or any investigational product(s) is/are administered, and answer  
all questions regarding the study and substudy.   
Participants must be informed that their participation is voluntary.  Participants will then 
be required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations,  ICH guidelines, Health Insurance Portability and 
Accountability Act requirements, where applicable, and the IRB/IEC  or study site.  
The subject’s medical record must include a statement that written informed consent 
was obtained before the subject was enr olled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must also 
sign the informed consent form.  
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed 
of the subject’s participation in the clinical study unless it is a local requirement.  The 
investigator shall then inform the primary care physician.  If the subject agree s to such 
notification, the investigator is to inform the subject’s primary care physician of the 
subject’s participation in the clinical study.  If the subject does not have a primary care 
physician and the investigator will be acting in that capacity, th e investigator is to 
document such in the subject’s medical record.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 71 of 91 
CONFIDENTIAL    
The acquisition of informed consent and the subject’s agreement or refusal of his/her 
notification of the primary care physician  is to be documented in the subject’s medical 
records, and t he informed consent form is to be signed and personally dated by the 
subject and by the person who conducted the informed consent discussion.  Subject 
withdrawal of consent or discontinuation from study treatment and/or procedures must 
also be documented i n the subject’s medical records; refer to Section 7. 
Subjects must be re -consented to the most current version of the informed consent 
form(s) during their participation in the study.  
The original signed informed consent form is to be retaine d in accordance with 
institutional policy, and a copy of the informed consent form(s) must be provided to the 
subject or the subject’s legally authorized representative.  
Data Protection/Subject Confidentiality  
The investigator must ensure that the subject ’s confidentiality is maintained for 
documents submitted to Amgen.  
The subject will be assigned a unique identifier by the sponsor.  Any subject records or 
datasets that are transferred to the sponsor will contain the identifier only; subject names 
or any information which would make the subject identifiable will not be transferred.  
On the electronic Case Report Form (eCRF) demographics page, in addition to the 
unique subject identification number, include the age at time of enrollment.  
For serious adverse  events reported to Amgen, subjects are to be identified by their 
unique subject identification number, initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations).  
Documents that are  not submitted to Amgen (eg, signed informed consent forms) are to 
be kept in confidence by the investigator, except as described below.  
Subject data should be kept in a secure location.  Access to subject data will be limited 
to authorized individuals, as  described below.  
In compliance with governmental regulations/ICH GCP Guidelines , it is required that the 
investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the IRB/IEC  direct access to review th e subject’s original 
medical records for verification of study -related procedures and data.  Direct access 
includes examining, analyzing, verifying, and reproducing any records and reports that 
are important to the evaluation of the study.   
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 72 of 91 
CONFIDENTIAL    
The investigat or is obligated to inform and obtain the consent of the subject to permit 
such individuals to have access to his/her study -related records, including personal 
information.  
Amgen complies with all relevant and applicable laws and regulations that protect 
personal information in order to ensure subject confidentiality and privacy.  Subjects are 
designated by a unique subject identification number in the Sponsor’s systems.  The  
Sponsor uses  access -controlled systems to house, review, and analyze subject data.  
These systems are backed up regularly to minimize the risk of loss of subject data; 
procedures are also defined for data recovery in the event of data loss.  The Sponsor 
has standard operating procedures in place that restrict access to subject data to those 
who require access to this data based on their role and have also completed the 
required training.  These procedures also outline the process for revoking access to 
such data when it is no longer needed.  In the event of a security breach, the Sponsor 
has procedures in place for notification of privacy incidents and to address these 
incidents, via its Business Conduct Hotline.  
Publication Policy  
Authorship of any publications resulting from this study will be determined on the basis 
of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals 
International Committee of Medical Journal Editors Recommendations for the Conduct of 
Reporting, Editing, and  Publications of Scholarly Work in Medical Journals, which states:  
Authorship credit is to be based on:  (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the article 
or revis ing it critically for important intellectual content; (3) final approval of the version to 
be published; and (4) agreement to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any part of the work  are 
appropriately investigated and resolved.  Authors need to meet conditions 1, 2, 3, and 4.  
When a large, multicenter group has conducted the work, the group is to identify the 
individuals who accept direct responsibility for the manuscript.  These indi viduals must 
fully meet the criteria for authorship defined above. Acquisition of funding, collection of 
data, or general supervision of the research group, alone, does not justify authorship.  All 
persons designated as authors must qualify for authorship,  and all those who qualify are 
to be listed.   Each author must have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. All publications (eg, manuscripts, 
abstracts, oral/slide presentations, book c hapters) based on this study must be 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 73 of 91 
CONFIDENTIAL    
submitted to Amgen for review.  The Clinical Trial Agreement among the institution, 
investigator, and Amgen will detail the procedures for, and timing of, Amgen’s review of 
publications.  
Investigator Signatory Obligatio ns 
Each clinical study report is to be signed by the investigator or, in the case of multicenter 
studies, the coordinating investigator.  
The coordinating investigator, identified by Amgen, will be any or all of the following:  
 A recognized expert in the the rapeutic area  
 An Investigator who provided significant contributions to either the design or 
interpretation of the study  
 An Investigator contributing a high number of eligible subjects  
Data Quality Assurance  
All subject data relating to the study will be r ecorded on printed or electronic CRF 
(eCRF) unless transmitted to the sponsor or designee electronically (eg, laboratory data, 
centrally or adjudicated data).  The investigator is responsible for verifying that data 
entries are accurate and correct by phys ically or electronically signing the eCRF.  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulator y agency inspections and provide direct access to source data documents.   
The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
Clinical monitors will perform ongoing source data verification  to confirm that data 
entered into the eCRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of subjects are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements per the sponsor’s monitoring plan.  
The investigator agrees to cooperate with the clinical monitor to ensure that any 
problems detected in the c ourse of these monitoring visits, including delays in 
completing eCRFs, are resolved.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 74 of 91 
CONFIDENTIAL    
The Amgen representative(s) and regulatory authority inspectors are responsible for 
contacting and visiting the investigator for the purpose of inspecting the facilities and, 
upon request, inspecting the various records of the clinical study (eg, eCRFs and other 
pertinent data) provided that subject confidentiality is respected.  
In accordance with ICH GCP and the sponsor’s audit plans, this study may be selected 
for audit by representatives from Amgen’s Global Research and Development 
Compliance and Audit function (or designees).  Inspection of site facilities (eg, 
pharmacy, protocol -required therapy storage areas, laboratories) and review of 
study -related records will occu r to evaluate the study conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
Quality tolerance limit parameters (QTLs) will be pre -defined in the QTL definitions table 
to identify possible systematic issues that can im pact participant safety and/or reliability 
of the study results.  These pre -defined parameters will be monitored during the study.  
Important deviations from the QTL threshold limits for these parameters and remedial 
actions taken will be summarized in the  clinical study report.  
Retention of study documents will be governed by the Clinical Trial Agreement.  
All written information and other material to be used by subjects and investigative staff 
must use vocabulary and language that are clearly understood.  
Source Documents  
The investigator is to maintain a list of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or corrections 
on eCRFs will be included on the Amgen Delegation of Authority Form.  
Source documents provide evidence for the existence of the subject and substantiate 
the integrity of the data collected.  Source documents are filed at the investigator’s site.  
Source documents are original documents, data, and records from which the  subject’s 
eCRF data are obtained.  These include but are not limited to hospital records, clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, 
and correspondence.  Source documents may also include data captured in the 
Interactive Response Technology (IRT) system (if used, such as subject ID and 
randomization number) and eCRF entries if the eCRF is the site of the original recording 
(ie, there is no other written or electronic record of data, such as paper questio nnaires 
for a clinical outcome assessment or certain demographic information).  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 75 of 91 
CONFIDENTIAL    
Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may ne ed to request previous medical records or transfer records, 
depending on the study.  Also, current medical records must be available.  
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all stud y-related (essential) documentation, suitable for 
inspection at any time by representatives from Amgen and/or applicable regulatory 
authorities.  
Elements to include:  
 Subject files containing completed eCRFs, informed consent forms, and subject 
identification list  
 Study files containing the protocol with all amendments, Investigator’s Brochure, 
copies of prestudy documentation, and all correspondence to and from the IRB/IEC 
and Amgen  
 Investigational product -related correspondence including Proof of Receipts, 
Investigational Product Accountability Record(s), Return of Investigational Product 
for Destruction Form(s), and Final Investigational Product Reconciliation Statement, 
as applicable  
 Non-investigational product(s), and/or medical device(s) or combination product(s) 
documentation, as applicable  
Retention of study documents will be governed by the Clinical Trial Agreement.  
Study and Site Closure  
Amgen or its designee may stop the study or study site participation in the study for 
medical, safety,  regulatory, administrative, or other reasons consistent with applicable 
laws, regulations, and GCP.  
Both Amgen and the Investigator reserve the right to terminate the Investigator’s 
participation in the study according to the Clinical Trial Agreement.  T he investigator is to  
notify the IRB/IEC  in writing of the study’s completion or early termination and send a 
copy of the notification to Amgen.  
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
by a separate protocol o r as provided for by the local country’s regulatory mechanism.  
However, Amgen reserves the unilateral right, at its sole discretion, to determine 
whether to supply Amgen investigational product(s) and by what mechanism, after 
termination of the study and before the product(s) is/are available commercially.  
 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 76 of 91 
CONFIDENTIAL    
Compensation  
Any arrangements for compensation to subjects for injury or illness that arises in the 
study are described in the Compensation for Injury section of the Informed Consent that 
is available a s a separate document.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 77 of 91 
CONFIDENTIAL    
11.4 Appendix 4.  Safety Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  
Definition of Adverse Event  
Adverse Event Definition  
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the study treatment.   
 Note:  An adverse event can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory  finding), symptom, or disease (new or 
exacerbated) temporally associated with the use of a treatment, combination 
product, medical device or procedure.  
 Note:  Treatment -emergent adverse events will be defined in the SAP.  
 
Events Meeting the Adverse Event  Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, electrocardiogram, radiological scans, vital signs 
measurements), including those that worsen from baseline, that are considered 
clinically significant in the medical and scientific judgment of the investigator (ie, 
not related to progression of underlying disease).  
 Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication.  Overdose per se will not be reported as an 
adverse event/serious adverse event unless it is an intentional overdose taken with 
possib le suicidal/self -harming intent.  Such overdoses are to be reported 
regardless of sequelae.  
  “Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an adverse event or serious adverse event.  Such instances will b e 
captured in the efficacy assessments.  However, the signs, symptoms, and/or 
clinical sequelae resulting from lack of efficacy will be reported as adverse event or 
serious adverse event if they fulfill the definition of an adverse event or serious 
adverse  event.  
 
Events NOT Meeting the Adverse Event Definition  
 Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that 
leads to the procedure is the adverse event.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 78 of 91 
CONFIDENTIAL    
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Definition of Serious Adverse Event  
A Serious Adverse Eve nt is defined as any untoward medical occurrence that, 
meets at least 1 of the following serious criteria:  
Results in death (fatal)  
Immediately life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event.  It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
Requires in -patient hospitalization or prolongation of existing hospitalization  
In general, hospit alization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting.  Complications that occur during hospitalization are an adverse 
event.  If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious.  When in doubt as to whether “hospitalization” occurred or was 
necessary, the ad verse event is to be considered serious.  Hospitalization for elective 
treatment of a pre -existing condition that did not worsen from baseline is not 
considered an adverse event.  
Results in persistent or significant disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  This definition is not intended to include experiences of relatively 
minor medical significance such as uncomplicated headache, nausea, vomiting, 
diarrhea, i nfluenza, and accidental trauma (eg, sprained ankle) which may interfere 
with or prevent everyday life functions but do not constitute a substantial disruption.  
Is a congenital anomaly/birth defect  
Other medically important serious event  
Medical or scien tific judgment is to be exercised in deciding whether serious adverse 
event reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospitalization but may 
jeopardize the subject or may require medical or surgical intervention to prevent 1 of 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 79 of 91 
CONFIDENTIAL    
the other outcomes listed in the above definition.  These events are typically to be 
considered serious.  
Examples of such events include invasive or malignant cancers, intensive tr eatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.  
 
Definition of Adverse Device Effect  
The detection and documentation  procedures for adverse device effects described in 
this protocol apply to all Amgen medical devices provided for use in the study (see 
Section 6.1.3  for the list of Amgen  medical devices).  
Adverse Device Effect Definition  
An adverse device effect is any adverse event related to the use of a combination 
product or medical device.  Adverse  device effects include, but are not limited to, 
adverse events resulting from insufficient or inadequate instructions for use, adverse 
events resulting from any malfunction of the device, or adverse events resulting from 
use error or from intentional misu se of the device.  
A combination product is a product composed of any combination of a drug, a 
device, and a biological product.  Each drug, device, and biological product 
included in a combination product is referred to as a “constituent part” of the 
combination product.  
Recording Adverse Events and Serious Adverse Events  
Adverse Event and Serious Adverse Event Recording  
 When an adverse event or serious adverse event occurs, it is the responsibility of 
the investigator to review all documentation (eg, hospital progress notes, 
laboratory, and diagnostics reports) related to the event.  
 The investigator will then record all relevant adverse event/serious adverse event 
information in the Event electronic case report form (eCRF).  
 The investigator must assign the following mandatory adverse event attributes:  
 Adverse event diagnosis or syndrome(s), if known (if not known, signs or 
symptom s); 
 Dates of onset and resolution (if resolved);  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 80 of 91 
CONFIDENTIAL    
 Did the event start prior to first dose of investigational product, other protocol -
required therapies;  
 Assessment of seriousness;  
 Severity (or toxicity defined below);  
 Assessment of relatedness to investigat ional product, devices, and/or study -
mandated activity and/or procedures;  
 Action taken; and  
 Outcome of event.  
 If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity on the Event eCRF . 
 It is not acceptable for the investigator to send photocopies of the subject’s medical 
records to the sponsor in lieu of completion of the Event eCRF page.  
 If specifically requested, the investigator may need to provide additional follow -up 
information, such as discharge summaries, medical records, or extracts from the 
medical records.  In this case, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records before 
submission to Amgen. 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the adverse event/serious 
adverse event.  
Evaluating Adverse Events and Serious Adverse Events  
Assessment of Severity  
The investigator will make an assessment of severity for each adverse event and 
serious adverse event reported during the study.  The assessment of severity will be 
based on: 
The Common Terminology Criteria for Adverse Events , version 4.03, which is 
available at the following location:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between investigational 
product , device(s), and/or study -mandated activity and/or procedure(s) and each 
occurrence of each adverse event/serious adverse event.  
 Relatedness means that there are facts or reasons to support a relationship 
between investigational product and the event.  
 The investigator will use clinical judgment to determine the relatio nship.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 81 of 91 
CONFIDENTIAL    
 Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
 The investigator will also consu lt the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment.  
 For each adverse event/serious adverse event, the investigator must document in 
the medical notes that he/she has reviewed the adverse event/serious ad verse 
event and has provided an assessment of causality.  
 There may be situations in which a serious adverse event has occurred and the 
investigator has minimal information to include in the initial report.  However, it is 
very important that the investigat or always make an assessment of causality for 
every event before the initial transmission of the serious adverse event data.  
 The investigator may change his/her opinion of causality in light of follow -up 
information and send a serious adverse event follow -up report with the updated 
causality assessment.  
 The causality assessment is 1 of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of Adverse Event and Serious Adverse Event  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by 
Amgen  to elucidate the nature and/or causality of the adverse event or serious 
adverse event as fu lly as possible.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health 
care professionals.  
 If a subject is permanently withdrawn from protocol -required therapies because of 
a seri ous adverse event, this information must be submitted to Amgen.  
 If a subject dies during participation in the study or during a recognized follow -up 
period, the investigator will provide Amgen with a copy of any post -mortem 
findings including histopatholog y. 
 New or updated information will be recorded in the originally completed Event 
eCRF.  
 The investigator will submit any updated serious adverse event data to Amgen  
within 24 hours of receipt of the information.  
Reporting of Serious Adverse Event  
Serious Adverse Event Reporting via Electronic Data Collection Tool  
 The primary mechanism for reporting serious adverse event will be the electronic 
data capture (EDC) system.  
 If the EDC system is unavailable for more than 24 hours, then the site will report 
the information to Amgen using a paper -based Serious Adverse Event 
Contingency Report Form (see  Figure 11 -1) within 24 hours of the investigator’s 
awareness  of the event.  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 82 of 91 
CONFIDENTIAL    
 The site will enter the serious adverse event data into the electronic system as 
soon as it becomes available.  
 After the study is completed at a given site, the EDC system will be taken off -line to 
prevent the entry of new data or changes to  existing data.  
 If a site receives a report of a new serious adverse event from a study subject or 
receives updated data on a previously reported serious adverse event after the 
EDC system has been taken off -line, then the site can report this information on a 
paper Serious Adverse Event Contingency Report Form (see  Figure 11 -1). 
 Once the study has ended, serious adverse event(s) suspected to be related 
to investigational product will be reported to Amgen if the investigator 
becomes aware of a serious adverse event.  The investigator should use the 
paper -based Serious Adverse Event Contingency Report Form to report the 
event.  
Adverse Device Effects:  Recording, Evaluating and Reporting  
 Any adverse event resulting from an adverse device effect that occur during the 
study will be documented in the subject’s medical records, in accordance with the 
investigator’s normal clinical practice, and on the Event eCRF page.  
 It is very important that the investigator provides his/her assessment of causality 
(relationship to the medical device provided by Amgen ) at the time of the initial report 
and describes any corrective or remedial actions taken to prevent recurr ence of the 
incident.  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 83 of 91 
CONFIDENTIAL    
Figure 11-1.  Sample Electronic Serious Adverse Event Contingency Report Form 
(paper -based form)  
 
 
 

Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 84 of 91 
CONFIDENTIAL    
 
 
 
 

Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 85 of 91 
CONFIDENTIAL    
 
  

Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 86 of 91 
CONFIDENTIAL    
11.5 Appendix 5.  Contraceptive Guidance and Collection of Pregnancy 
and Lactation Information  
Study -specific contraception requirements for female subjects of childbearing potential 
are outlined in Section 5.2. 
Female subjects of childbearing potential must receive pregnancy prevention counseling 
and be advised of the  risk to the fetus if they become pregnant during treatment and for 
an additional 16 weeks after the last dose of IP.  
Definition of Females of Childbearing Potential  
A female is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile.  Permanent sterilization methods include hysterectomy, 
bilateral salpingectomy, and bilateral oophorectomy.  
Females in the following categories are not considered female of childbearing potential:  
 premenopausal female with 1 of the following:  
o documented hysterectomy;  
o documented bilateral salpingectomy; or  
o documented bilateral oophorectomy.  
Note: Site personnel documenta tion from the following sources is acceptable:  
1) review of subject’s medical records; 2) subject’s medical examination; or 
3) subject’s medical history interview.  
 premenarchal female  
 postmenopausal female  
o A postmenopausal state is defined as no menses fo r 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormone replacement therapy 
(HRT). Howe ver, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient.  
o Females on HRT and whose menopausal status is in doubt will be required to 
use 1 of the non -hormonal highly effective contraception methods if they wish to 
continue t heir HRT during the study. Otherwise, they must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.  
Contraception Methods for Female Subjects  
Acceptable Methods of Effective Contraception  
 Combined (estrogen and progestogen containing) or progestogen -only hormonal 
methods given via oral, intravaginal, transdermal, injectable, or implantable route)  
 Intrauterine device  
 Intrauterine hormonal -releasing system  
 Bilateral tubal ligation/occlusion  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 87 of 91 
CONFIDENTIAL    
 Vasectomized partner (pr ovided that partner is the sole sexual partner of the female 
subject of childbearing potential and that the vasectomized partner has received 
medical assessment of the surgical success)  
 Sexual abstinence (defined as refraining from heterosexual intercourse  during the 
entire period of risk associated with the study treatments; the reliability of sexual 
abstinence must be evaluated in relation to the duration of the trial and the preferred 
and usual lifestyle of the subject)  
 Male or female condom with or with out spermicide  
 Cap, diaphragm or sponge with spermicide  
 Double barrier method:  the male uses a condom and the female may choose either 
a cap, diaphragm, or sponge with spermicide (a female condom is not an option due 
to the risk of tearing when both partn ers use a condom)  
Unacceptable Methods of Birth Control for Female Subjects  
Birth control methods that are considered unacceptable in clinical trials include:  
 Periodic abstinence (calendar, symptothermal, postovulation methods)  
 Withdrawal (coitus interruptus)  
 Spermicides only  
 Lactational amenorrhea method  
Collection of Pregnancy Information  
Female Subjects Who Become Pregnant  
 Investigator will collect pregnancy information on any female subject who becomes 
pregnant while taking protocol -required th erapies through  16 weeks after the last 
dose of protocol -required therapies . 
 Information will be recorded on the Pregnancy Notification Form (see  Figure  11-2).  
The form must be submitted to Amgen Global Patient Safety within 24 hours of the 
site’s awareness of a subject’s pregnancy.  (Note: Sites are not required to provide 
any information  on the Pregnancy Notification Form that violates the country or 
regions local privacy laws).  
 After obtaining the female subject’s signed consent for release of pregnancy and 
infant health information, the investigator will collect pregnancy and infant hea lth 
information and complete the pregnancy questionnaire for any female subject who 
becomes pregnant while taking IP through 16 weeks after the last dose of the study 
drug.  This information will be forwarded to Amgen Global Patient Safety.  Generally, 
infant follow -up will be conducted up to 12  months after the birth of the child (if 
applicable).  
 Any termination of pregnancy will be reported to Amgen Global Patient Safety, 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
 While pregnancy itself is not considered to be an adverse event or serious adverse 
event, any pregnancy complication or report of a congenital anomaly or 
developmental delay, fetal death, or suspected adverse reactions in the neonate will 
be report ed as an adverse event or serious adverse event.  Note that an elective 
termination with no information on a fetal congenital malformation or maternal 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 88 of 91 
CONFIDENTIAL    
complication is generally not considered an adverse event, but still must be reported 
to Amgen as a pregn ancy exposure case.  
 If the outcome of the pregnancy meets a criterion for immediate classification as a 
serious adverse event (eg, female subject experiences a spontaneous abortion, 
stillbir th, or neonatal death or there is a fetal or neonatal congenital anomaly) the 
investigator will report the event as a serious adverse event.  
 Any serious adverse event occurring as a result of a post -study pregnancy which is 
considered reasonably related to  the study treatment by the investigator, will be 
reported to Amgen Global Patient Safety as described in Section 11.4.  While the 
investigator is n ot obligated to actively seek this information in former study subjects, 
he or she may learn of a serious adverse event through spontaneous reporting.  
 Any female subject who becomes pregnant while participating will discontinue study 
treatment (see Section 7.1 for deta ils). 
Male Subjects With Partners Who Become Pregnant  
 In the event a male subject fathers a child during treatment, and for an additional 
16 weeks after  discontinuing protocol -required therapies, the information will be 
recorded on the Pregnancy Notification Form.  The form ( see Figure 11 -2) must be 
submitted to Amgen Global Patient Safety within 24 hours of the site’s awareness of 
the pregnancy.  (Note: Sites are not required to provide any information on t he 
Pregnancy Notification Form that violates the country or regions local privacy laws).  
 The investigator will attempt to obtain a signed consent for release of pregnancy and 
infant health information directly from the pregnant female partner to obtain 
additional pregnancy information.  
 After obtaining the female partner’s signed consent for release of pregnancy and 
infant health information, the investigator will collect pregnancy outcome and infant 
health information on the pregnant partner and her baby an d complete the 
pregnancy questionnaires.  This information will be forwarded to Amgen Global 
Patient Safety.  
 Generally, infant follow -up will be conducted up to 12 months after the birth of the 
child (if applicable).  
 Any termination of the pregnancy will be reported to Amgen Global Patient Safety 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
Collection of Lactation Information  
 Investigator will collect lactation information on any female subject who breastfeeds 
while taking protocol -required therapies through 16 weeks after the last dose of study 
drug.  
 Information will be recorded on the Lactation Notification Form (see below) a nd 
submitted to Amgen Global Patient Safety within 24 hours of the investigator’s 
awareness of the event.  
 Study treatment will be discontinued if female subject breastfeeds during the study 
as described in exclusion criterion 218. 
 With the female subjects signed consent for release of mother and infant health 
information, the investigator will collect mother and infant health information and 
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 89 of 91 
CONFIDENTIAL    
complete the lactation questionnaire on any female subject who breastfeeds while 
taking protocol -required therapies t hrough 16 weeks after discontinuing IP.  
  
Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 90 of 91 
CONFIDENTIAL    
Figure 11-2.  Pregnancy and Lactation Notification Forms  
 
 

Product:   Erenumab -aooe  (AMG 334)  
Protocol Number:   20190389  
Date:   18 March 2022  Page 91 of 91 
CONFIDENTIAL    
 
 

Product:  Erenumab -aooe (AMG 334)  
Protocol Number:  20190389  
Date:  18 March  2022  Page 1 of 17 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Amendment 2 
Protocol Title:  Phase  4, Open -label Study to Evaluate Treatment Satisfaction With 
Erenumab in Patients With Migraine  
 
Amgen Protocol Number 20190389  
 
Amendment Date:  18 March  2022  
 
Rationale:  
This protocol is being amended to remove restrictions to inclusion criteria and to update 
the list of excluded medications in order to encourage study enrolment.  
Amendments to the protocol include:  
 Remov al of the prior anti -calcitonin gene related peptide  exposure exclusion  
 Remov al of the restriction of the use of concomitant botulinum toxin  
 Clarif ication of  the definition of episodic migraine  in the protocol  
 Clarif ication of  the excluded medications in the protocol  
 Update to the safety reporting language in the protocol based on the protocol 
template .  
 Update of administrative details , correct ion of  formatting  and typographical errors 
throughout the document  
Product:  Erenumab -aooe (AMG 334)  
Protocol Number:  20190389  
Date:  18 De cember 2020  Page 1 of 22 
Amgen Proprietary - Confidential  Amendment 1 
Protocol Title:  Phase 4, Open -label Study to Evaluate Treatment Satisfaction With 
Erenumab in Patients With Migraine  
 
Amgen Protocol Number 20190389  
 
Amendment Date:  18 December 2020  
 
Rationale:  
The protocol is being amended to:  
 Remove Schedule of Activities for clinicians as it no longer applies  
 Clarify scale of measurement for migraine Global Impression Item (mGI -I) 
 Remove references to clinician consent as consent is not required  
 Clarify consent requirements for subjects and key family members  
 Clarify on -study exclusionary procedure requirements  
 Clarify how medications will be recorded  
 Clarify local lab requirements  
 Correct grammatical and typographical errors througho ut 
 
 
 
Product:  Erenumab -aooe (AMG 334)  
Protocol Number:  20190389  
Date:  20 November 2020  Page 1 of 1 
Amgen Proprietary - Confidential  Superseding Original Amendment  
Protocol Title:  Phase 4, Open -label Study to Evaluate Treatment Satisfaction With 
Erenumab in Patients With Migraine  
 
Amgen Protocol Number 20190389  
 
Amendment Date:  20 November 2020  
 
Rationale:  
Clarify the intent  of exclusion criterion 204  
 
Description of Changes  
Section 5.2, Exclusion Criterion 204  
Replace:   
Malignancy (except non -melanoma skin cancers, cervical or breast ductal carcinoma in 
situ within the last 5 years)  
With:    
Malignancy (except non -melanoma skin cancers, cervical or breast ductal carcinoma in 
situ) within the last 5 years ) 
 
 
 